10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2019

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 000-55863

RAFAEL HOLDINGS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	82-2296593
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)
520 Broad Street, Newark, New Jersey	07102
(Address of principal executive offices)	(Zip Code)

(212) 658-1450

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Class B common stock	RFL	NYSE American

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☒
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.): Yes ☐ No ☒

The number of shares outstanding of the registrant’s common stock as of June 4, 2019 was:

Class A common stock, par value $0.01 per share:	787,163 shares
Class B common stock, par value $0.01 per share:	13,142,502 shares

RAFAEL HOLDINGS, INC.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION		1
Item 1.	Financial Statements (Unaudited)	1
	Consolidated Balance Sheets as of April 30, 2019 and July 31, 2018	1
	Consolidated and Combined Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended April 30, 2019 and 2018	2
	Consolidated and Combined Statements of Cash Flows for the Nine Months Ended April 30, 2019 and 2018	3
	Consolidated Statements of Stockholder’s Equity for the Three and Nine Months Ended April 30, 2019 and 2018	4 - 5
	Notes to Consolidated and Combined Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3.	Quantitative and Qualitative Disclosures About Market Risks	22
Item 4.	Controls and Procedures	22
PART II. OTHER INFORMATION		23
Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	23
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.	Defaults upon Senior Securities	23
Item 4.	Mine Safety Disclosures	23
Item 5.	Other Information	23
Item 6.	Exhibits	24
SIGNATURES		25

i

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

RAFAEL HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS

(unaudited, in thousands, except share data)

	April 30,			July 31,
	2019			2018
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	12,969		$	15,803
Trade accounts receivable, net of allowance for doubtful accounts of $86 and $82 at April 30, 2019 and July 31, 2018		672			287
Marketable securities		—			24,701
Due from Rafael Pharmaceuticals		160			3,300
Prepaid expenses and other current assets		840			421
Total current assets		14,641			44,512
Property and equipment, net		49,181			50,113
Investments – Rafael Pharmaceuticals		70,018			13,300
Investments – Other Pharmaceuticals		2,000			2,000
Investments – Hedge Funds		4,632			4,218
Deferred income tax assets, net		24			—
Patents		407			324
In-process research and development		1,327			1,327
Other assets		1,223			1,126
Total assets	$	143,453		$	116,920
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Trade accounts payable	$	755		$	367
Accrued expenses		203			500
Other current liabilities		19			24
Total current liabilities		977			891
Due to/from related parties		44			276
Convertible note, net of $60 discount – Related Party		14,940			—
Accrued interest on convertible note – Related Party		418			—
Other liabilities		210			188
Total liabilities		16,589			1,355
Commitments and contingencies
STOCKHOLDERS’ EQUITY
Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of April 30, 2019 and July 31, 2018		8			8
Class B common stock, $0.01 par value; 200,000,000 shares authorized, 13,139,333 and 11,762,346 shares issued and outstanding as of April 30, 2019 and July 31, 2018, respectively		131			118
Additional paid in capital		117,383			103,636
Accumulated deficit		(3,654	)		(1,108	)
Accumulated other comprehensive income		4,134			4,043
Total Rafael Holdings, Inc. stockholders’ equity		118,002			106,697
Noncontrolling interests		8,862			8,868
Total equity		126,864			115,565
Total liabilities and STOCKHOLDERS’ equity	$	143,453		$	116,920

See accompanying notes to consolidated financial statements.

1

RAFAEL HOLDINGS, INC.

CONSOLIDATED AND COMBINED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited, in thousands, except share data)

	Three Months Ended April 30,						Nine Months Ended April 30,
	2019			2018			2019			2018
Revenues:
Rental – Third Party	$	588		$	400		$	1,277		$	1,085
Rental – Related Party		521			447			1,564			1,442
Parking		268			246			688			630
Total Revenue		1,377			1,093			3,529			3,157
Costs and expenses:
Selling, general and administrative		2,059			1,402			5,228			4,481
Research and development		300			—			949			—
Depreciation and amortization		436			422			1,296			1,276
Loss from operations		(1,418	)		(731	)		(3,944	)		(2,600	)
Interest (expense) income, net		(221	)		71			647			75
Net gain (loss) resulting from foreign exchange transactions		19			(28	)		19			90
Net loss on equity investments		—			—			—			(104	)
Gain on sales of marketable securities, net		—			24			330			24
Unrealized gain on investments – Hedge Funds		466			—			414			—
Gain on disposal of bonus shares		—			—			—			246
Loss before income taxes		(1,154	)		(664	)		(2,534	)		(2,269	)
Benefit from (provision for) income taxes		7			5			21			(8,438	)
Net Loss		(1,147	)		(659	)		(2,513	)		(10,707	)
Net loss attributable to noncontrolling interests		(142	)		(128	)		(6	)		(304	)
Net loss attributable to Rafael Holdings, Inc.	$	(1,005	)	$	(531	)	$	(2,507	)	$	(10,403	)
OTHER COMPREHENSIVE LOSS
Net Loss	$	(1,147	)	$	(659	)	$	(2,513	)	$	(10,707	)
Unrealized loss on marketable securities		—			(311	)		—			(311	)
Foreign currency translation adjustments		(54	)		(85	)		(52	)		(10	)
Total Comprehensive Loss		(1,201	)		(1,055	)		(2,565	)		(11,028	)
Comprehensive (loss) income attributable to noncontrolling interests		(18	)		(29	)		5			(29	)
Total Comprehensive Loss attributable to Rafael Holdings, Inc.	$	(1,183	)	$	(1,026	)	$	(2,570	)	$	(10,999	)
Loss Per Share attributable to Rafael Holdings Inc. common shareholders:
Basic and diluted	$	(0.07	)	$	(0.04	)	$	(0.19	)	$	(0.83	)
Weighted average number of shared used in calculation of loss per share:
Basic and diluted		13,924,691			12,541,998			13,055,037			12,541,998

See accompanying notes to consolidated and combined financial statements.

2

RAFAEL HOLDINGS, INC.

 CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS

(unaudited, in thousands, except share data)

	Nine Months Ended April 30,
	2019			2018
Operating activities
Net loss	$	(2,513	)	$	(10,403	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,296			1,276
Deferred income taxes		(24	)		8,851
Interest income on Rafael Pharmaceuticals Series D Convertible Note		(848	)		—
Net gain on sale of marketable securities		(330	)		(24	)
Unrealized gain on investments – Hedge Funds		(414	)		—
Provision for doubtful accounts		86			—
Realized gain on disposal of bonus shares		—			(246	)
Non-cash compensation		269			616
Amortization of debt discount		11			—
Interest in the equity of investments		—			(80	)
Change in assets and liabilities:
Trade accounts receivable		(471	)		(142	)
Other current assets and prepaid expenses		(419	)		(392	)
Other assets		(180	)		(355	)
Accounts payable and accrued expenses		91			223
Other current liabilities		(5	)		(8	)
Due to/from related parties		473			(386	)
Accrued interest – Related Party		418			—
Other liabilities		22			—
Net cash used in operating activities		(2,538	)		(1,070	)
Investing activities
Purchases of property and equipment		(364	)		(572	)
Proceeds from sale and maturity of marketable securities, net		25,031			436
Investment in Rafael Pharmaceuticals		(55,870	)		—
Net cash used in investing activities		(31,203	)		(136	)
Financing activities
Contribution from noncontrolling interest of consolidated entity		4,587			—
Repayment of Due from Rafael Pharmaceuticals		3,300			—
Proceeds from exercise of options		190			—
Proceed from sale of Class B Common shares to Related Party		7,777			—
Proceeds from issuance of convertible note payable - Related Party		15,000			—
Net cash provided by financing activities		30,854			—
Effect of exchange rate changes on cash and cash equivalents		53			55
Net decrease in cash and cash equivalents		(2,834	)		(1,151	)
Cash and cash equivalents at beginning of period		15,803			11,756
Cash and cash equivalents at end of period	$	12,969		$	10,605
Supplemental Schedule of Non-Cash Investing and Financing Activities
Adoption effect of ASU 2016-01	$	39		$	—
Beneficial conversion feature of convertible debt – Related Party	$	71		$	—
Series D Convertible Note and accrued interest converted to Series D Preferred Stock	$	10,848		$	—
Related Party deposit utilized to purchase Class B Common Stock	$	864		$	—
Cash payments made for interest & taxes	$	—		$	—

See accompanying notes to consolidated and combined financial statements.

3

RAFAEL HOLDINGS, INC.

CONSOLIDATED AND COMBINED STATEMENTS OF SHAREHOLDER’S EQUITY

(unaudited, in thousands, except share data)

Three Months Ended April 30, 2018
	Common Stock, Series A				Common Stock, Series B				Group			Additional Paid-in		Accumulated			Accumulated other comprehensive			Noncontrolling			Total Stockholders’
	Shares		Amount		Shares		Amount		Equity			Capital		Deficit			income			Interests			Equity
Balance at January 31, 2018		—	$	—		—	$	—	$	40,554		$	—	$	—		$	2,394		$	9,678		$	52,626
Incorporation of Company, Capital contribution from IDT and share distribution on Spin-Off		787,163		8		11,754,835		118		(40,215	)		103,499											63,410
Stock-based compensation													10											10
Unrealized Loss on Available-for-Sale Securities																		(311	)					(311	)
Foreign Currency Translation Adjustment																		(85	)		(41	)		(126	)
Net Loss										(339	)				(192	)					(128	)		(659	)
Balance at April 30, 2018		787,163	$	8		11,754,835	$	118	$	-		$	103,509	$	(192	)	$	1,998		$	9,509		$	114,950
Nine Months Ended April 30, 2018
	Common Stock, Series A				Common Stock, Series B				Group			Additional Paid-in		Accumulated			Accumulated other comprehensive			Noncontrolling			Total Stockholders’
	Shares		Amount		Shares		Amount		Equity			Capital		Deficit			income			Interests			Equity
Balance at July 31, 2017		—	$			—	$	—	$	50,426		$	—	$	—		$	2,316		$	9,335		$	62,077
Acquisition of LipoMedix																					559			559
Distribution of Rafael Pharmaceuticals Bonus Shares from IDT-Rafael Holdings to Rafael Holdings and Howard S. Jonas																					(40	)		(40	)
Incorporation of Company, Capital contribution from IDT and share distribution on Spin-Off		787,163		8		11,754,835		118		(40,215	)		103,499											63,410
Stock-based compensation													10											10
Unrealized Loss on Available-for-Sale Securities																		(311	)					(311	)
Foreign Currency Translation Adjustment																		(7	)		(41	)		(48	)
Net Loss										(10,211	)				(192	)					(304	)		(10,707	)
Balance at April 30, 2018		787,163	$	8		11,754,835	$	118	$	—		$	103,509	$	(192	)	$	1,998		$	9,509		$	114,950

4

RAFAEL HOLDINGS, INC.

CONSOLIDATED AND COMBINED STATEMENTS OF SHAREHOLDER’S EQUITY

(unaudited, in thousands, except share data)

Three Months Ended April 30, 2019
	Common Stock, Series A				Common Stock, Series B				Additional Paid-in		Accumulated			Accumulated other comprehensive		Noncontrolling			Total Stockholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			income		interests			Equity
Balance at January 31, 2019		787,163	$	8		13,133,069	$	131	$	117,258	$	(2,649	)	$	4,080	$	9,004		$	127,832
Stock Based Compensation						750				91										91
Stock Options Exercised						5,514				27										27
Restricted Stock Units issued										7										7
Foreign currency translation adjustments															54					54
Net Loss												(1,005	)				(142	)		(1,147	)
Balance at April 30, 2019		787,163	$	8		13,139,333	$	131	$	117,383	$	(3,654	)	$	4,134	$	8,862		$	126,864
Nine Months Ended April 30, 2019
	Common Stock, Series A				Common Stock, Series B				Additional Paid - in		Accumulated			Accumulated other comprehensive		Noncontrolling			Total Stockholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			income		interests			Equity
Balance at July 31, 2018		787,163	$	8		11,762,346	$	118	$	103,636	$	(1,108	)	$	4,043	$	8,868		$	115,565
Adoption effect of ASU 2016-01												(39	)		39					-
Stock Based Compensation										151										151
Stock Options Exercised						38,710				190										190
Restricted Stock Units issued						71,468		1		11										12
Stock Based Compensation to Board of Directors						12,609				107										107
Purchase of Class B Common Shares						1,254,200		12		8,630										8,642
Debt Discount on convertible debt										71										71
Capital Contribution from noncontrolling interest										4,587										4,587
Foreign currency translation adjustments															52					52
Net Loss												(2,507	)				(6	)		(2,513	)
Balance at April 30, 2019		787,163	$	8		13,139,333	$	131	$	117,383	$	(3,654	)	$	4,134	$	8,862		$	126,864

5

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1 — DESCRIPTION OF BUSINESS

Rafael Holdings, Inc., (“Rafael Holdings” or “the Company”), a Delaware corporation, owns interests in clinical pharmaceutical companies and owns commercial real estate assets. The assets are operated as two separate lines of business. The pharmaceutical holdings include preferred equity interests and a warrant to purchase equity interests in Rafael Pharmaceuticals, Inc., or Rafael Pharma, which is a clinical stage, oncology-focused, pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells, and a majority equity interest in LipoMedix Pharmaceuticals Ltd., or LipoMedix, an oncology company based in Israel. The commercial real estate holdings consist of the building at 520 Broad Street in Newark, New Jersey that houses headquarters for the Company, affiliated entities as well as third-party tenants, and an associated 800-car public garage, an office/data center building in Piscataway, New Jersey and a portion of a building in Israel.

On March 26, 2018, IDT Corporation, or IDT, the former parent corporation of the Company, completed a tax-free spinoff (the “Spin-Off”) of the Company’s capital stock, through a pro rata distribution of common stock to its stockholders of record as of the close of business on March 13, 2018.

The “Company” in these financial statements refers to Rafael Holdings on a consolidated basis from the date of the Spin-Off and on a combined basis from the date prior to the Spin-Off as if Rafael Holdings existed and owned the above interests in all periods presented.

All significant intercompany accounts and transactions have been eliminated in consolidation or combination.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited consolidated and combined financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included. Certain amounts in the prior period financial statements have been reclassified to conform with the current period presentation. These reclassifications had no effect on previously reported losses, total assets or stockholders equity.

The Company’s fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated (e.g., fiscal 2019 refers to the fiscal year ending July 31, 2019).

Operating results for the three and nine months ended April 30, 2019 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2019. The balance sheet at July 31, 2018 has been derived from the Company’s audited consolidated and combined financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended July 31, 2018, or the 2018 Form 10-K, as filed with the U.S. Securities and Exchange Commission (“SEC”).

6

Notes to Unaudited Consolidated and Combined Financial Statements (continued)

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates.

Revenue Recognition

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update, (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) or ASU 2014-09. The objective of the ASU is to establish a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers, which supersedes most of the existing revenue recognition guidance, including industry-specific guidance. The core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying the ASU, companies will perform a five-step analysis of transactions to determine when and how revenue is recognized. The five-step analysis consists of the following: (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations in the contract and (v) recognizing revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 applies to all contracts with customers except those that are within the scope of other topics in the FASB’s ASC. The Company adopted ASU 2014-09 effective August 1, 2018 using the modified retrospective approach. The Company reviewed all contracts that were not completed as of August 1, 2018 and the adoption did not have a material impact on the Company’s consolidated financial statements.

The Company disaggregates its revenue by source within its consolidated and combined statements of operations. As an owner and operator of real estate, the Company derives the majority of its revenue from leasing space to tenants at its properties. As a result, the majority of the Company’s revenue is accounted for pursuant to ASC 840 Leases or ASC 840 and is reflected within Rental Revenue in the consolidated and combined statements of operations. In addition, the Company earns revenue from recoveries from tenants, consisting of amounts due from tenants for common area maintenance, real estate taxes and other recoverable costs. Revenue from recoveries from tenants is recognized under the guidance within ASC 840 until the adoption of ASC 842, Leases in 2019 at which time it may fall within the guidance under Topic 606.

Contractual rental revenue is reported on a straight-line basis over the terms of the respective leases. Accrued rental income, included within Other Assets on the consolidated balance sheets, represents cumulative rental income earned in excess of rent payments received pursuant to the terms of the individual lease agreements. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent payments or parking customers to pay amounts due.

The Company also earns revenue from parking which is derived primarily from monthly and transient daily parking. In addition, the Company has certain lease arrangements for parking accounted for under the guidance in ASC 840. The monthly and transient daily parking revenue falls within the scope of ASC 606 and is accounted for at the point in time when control of the goods or services transfers to the customer and the Company’s performance obligation is satisfied, consistent with the Company’s previous accounting.

Recently Issued Accounting Pronouncements Not Yet Adopted

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of reviewing all contracts with suppliers, vendors, customers and other outside parties to identify whether such contracts contain an embedded lease as defined under the new guidance and whether there will be any impact of the pending adoption of the new standard on its consolidated financial statements. The Company intends to adopt the standard on August 1, 2019.

7

Notes to Unaudited Consolidated and Combined Financial Statements (continued)

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, that changes the impairment model for most financial assets and certain other instruments. For receivables, loans and other instruments, entities will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowance for losses. For available-for-sale debt securities with unrealized losses, entities will measure credit losses in a manner similar to current practice, except the losses will be recognized as allowances instead of reductions in the amortized cost of the securities. In addition, an entity will have to disclose significantly more information about allowances, credit quality indicators and past due securities. The new standard is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years and will be applied as a cumulative-effect adjustment to retained earnings. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and intends to adopt the standard on August 1, 2020.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash or ASU 2016-18. The new guidance is intended to reduce diversity in practice by adding or clarifying guidance on classification and presentation of changes in restricted cash on the statement of cash flows. ASU 2016-18 is effective for annual and interim periods beginning after December 15, 2017. The amendments in this Statement are required to be applied retrospectively to all periods presented. The Company adopted this guidance retrospectively on August 1, 2018 with no material impact on the Company’s financial position, results of operations or cash flows. On a prospective basis, ASU 2016-18 will only impact the Company’s financial position and cash flows to the extent it has restricted cash.

Recently Adopted Accounting Pronouncements

In January 2016, the FASB issued ASU 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which required us to prospectively record changes in the fair value of our equity investments, except for those accounted for under the equity method, in net income instead of in accumulated other comprehensive income.  The Company implemented ASU 2016-01 in the first quarter of fiscal 2019 effective August 1, 2018. A cumulative-effect adjustment was recorded as of August 1, 2018 to reclassify approximately $39,000 of unrealized loss on equity securities from accumulated other comprehensive income to retained earnings resulting in prior-periods no longer being comparable.

SEC Disclosure Update and Simplification

In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders’ equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders’ equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018. The first presentation of the changes in shareholders’ equity in accordance with the new guidance is included in this Quarterly Report.

NOTE 3 — INVESTMENT IN LIPOMEDIX

LipoMedix is a development-stage, privately held Israeli company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery.

The Company holds 50.6% of the issued and outstanding ordinary shares of LipoMedix and has consolidated this investment from the second quarter of fiscal 2018.

In April 2019, the Company provided no-interest bridge financing of $250,000 to LipoMedix (the “2019 Bridge Note”). The 2019 Bridge Note is automatically convertible into shares of LipoMedix as follows: (i) upon an issuance of an aggregate $2.0 million of additional equity securities (excluding the conversion of the Bridge Notes); or (ii) upon a liquidation or dissolution of LipoMedix or a sale of LipoMedix or its assets.  If converted, the 2019 Bridge Note will be converted into shares of the most senior class of equity of LipoMedix then issued.  If converted upon an equity financing, the 2019 Bridge Note will be converted at a conversion price per share that is equal to 75% of the price paid in the equity offering. If converted upon a liquidation or sale event, the 2019 Bridge Note will be converted at a conversion price per share that is equal to 75% of the per share distribution received by LipoMedix equity holders in connection with the event, or, if greater the Company will receive a payment equal to the 2019 Bridge Note ($250,000).  If none of such events occurs prior to September 28, 2019, the 2019 Bridge Note will be converted into the most senior class of shares LipoMedix has then issued at a conversion price per share equal to $0.53 (calculated on the basis of LipoMedix’s pre-money valuation of $5.0 million).

On July 2018, the Company provided no-interest bridge financing of $875,000 to LipoMedix (the “2018 Bridge Note”). The 2018 Bridge Note is convertible into shares of LipoMedix as follows: (i) upon an issuance of an aggregate $2.0 million of additional equity securities (excluding the conversion of the 2018 Bridge Note) (the “Financing”), the 2018 Bridge Note amount shall be converted into shares of LipoMedix of the same class and series with the same rights, preferences and privileges as shall be issued in the Financing at a conversion price per share equal to 75% or the lowest price per share paid by the investor(s) in the Financing; (ii) upon a Distribution Event (as defined in the Founder’s Agreement among LipoMedix and certain of its founders), the 2018 Bridge Note shall be converted into shares of the most senior class of shares of LipoMedix then issued, at a conversion price per share that is equal to 75% of the per share distribution received by LipoMedix equity holders in connection with the Distribution Event, or the Company shall be entitled to receive a redemption payment equal to the 2018 Bridge Note ($875,000); (iii) if neither a Financing nor Distribution Event occurs prior to January 6, 2020 (18 months following the effective date of the 2018 Bridge Note), the 2018 Bridge Note will be converted into the most senior class of shares LipoMedix has then issued at a conversion price per share equal to $0.53 (calculated on the basis of LipoMedix’s pre-money valuation of $5.0 million, divided by its fully diluted share capital as of July 6, 2018).

8

Notes to Unaudited Consolidated and Combined Financial Statements (continued)

NOTE 4 — MARKETABLE SECURITIES

During fiscal 2019, all marketable securities held by the Company were liquidated in connection with the partial exercise of the Rafael Pharmaceuticals warrant, see Note 10. There were no marketable securities held by the Company as of April 30, 2019.

Proceeds from maturities and sales of available-for-sale securities were approximately $0 and $25.0 million for the three and nine months ended April 30, 2019 and $436,000 for each of the three and nine months ended April 30, 2018, respectively. The net realized gain that was included in earnings as a result of sales was approximately $0 and $330,000 for the three and nine months ended April 30, 2019, respectively, and $24,000 for each of the three and nine months ended April 30, 2018. The Company uses the specific identification method in computing the gross realized gains and gross realized losses on the sales of marketable securities.

NOTE 5 — FAIR VALUE MEASURMENTS

The Fair Value Measurements and Disclosures topic of the FASB ASC requires disclosures about how fair value is determined for assets and liabilities and a hierarchy for which these assets and liabilities must be grouped is established, based on significant levels of inputs as follows:

Level 1 quoted prices in active markets for identical assets or liabilities;

Level 2 quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability; or

Level 3 unobservable inputs for the asset or liability, such as discounted cash flow models or valuations.

The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The following is a listing of the Company’s assets required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of April 30, 2019 and July 31, 2018:

	April 30, 2019
	Level 1		Level 2		Level 3		Total
Available-for-sale securities:	(unaudited, in thousands)
Hedge Funds	$	—	$	—	$	4,632	$	4,632
Total	$	—	$	—	$	4,632	$	4,632

	July 31, 2018
	Level 1		Level 2		Level 3		Total
Available-for-sale securities:	(unaudited, in thousands)
Marketable Securities	$	10,755	$	13,946	$	—	$	24,701
Hedge Funds		—		—		4,218		4,218
Rafael Pharmaceuticals convertible promissory notes		—		—		7,900		7,900
Total	$	10,755	$	13,946	$	12,118	$	36,819

At April 30, 2019 and July 31, 2018, the Company did not have any liabilities measured at fair value on a recurring basis.

9

Notes to Unaudited Consolidated and Combined Financial Statements (continued)

At July 31, 2018, the fair value of the Rafael Pharmaceuticals Series D Convertible Note, (the “Series D Note”) was classified as Level 3, was estimated based on a valuation of Rafael Pharmaceuticals by reference to recent transactions in its securities, the Series D Note investment, as well as utilizing a discounted cash flow technique under the Income Approach and other factors that could not be corroborated by the market. The Series D Note was converted into shares of Series D Convertible Preferred Stock of Rafael Pharmaceuticals in January 2019.

The following table summarizes the change in the balance of the Company’s assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3).

	Three Months Ended April 31,				Nine Months Ended April 31,
	2019		2018		2019			2018
	(unaudited, in thousands)
Balance, beginning of period	$	4,166	$	6,300	$	12,118		$	6,300
Conversion of Rafael Pharmaceuticals Series D Convertible Note		—		—		(7,900	)		—
Total gains included in earnings		466		—		414			—
Balance, end of period	$	4,632	$	6,300	$	4,632		$	6,300

Prior to the Spin-Off, IDT contributed a $2.0 million investment in securities of another entity that are not liquid, which were included in “Investments – Other Pharmaceuticals” in the accompanying consolidated balance sheets. The investment is accounted for using the cost method; therefore, this investment is not measured at fair value.

Fair Value of Other Financial Instruments

The estimated fair value of the Company’s other financial instruments was determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting these data to develop estimates of fair value. Consequently, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange.

Cash and cash equivalents, prepaid expense and other current assets, and other current liabilities. At April 30, 2019 and July 31, 2018, the carrying amount of these assets and liabilities approximated fair value because of the short period of time to maturity. The fair value estimates for cash and cash equivalents were classified as Level 1 and other current assets, and other current liabilities were classified as Level 2 of the fair value hierarchy.

Other assets and other liabilities. At April 30, 2019 and July 31, 2018, the carrying amount of these assets and liabilities approximated fair value. The fair values were estimated based on the Company’s assumptions, which were classified as Level 3 of the fair value hierarchy.

The Company’s financial instruments include trade accounts receivable, trade accounts payable, and due from related parties. The recorded carrying amount of trade accounts receivable, trade accounts payable and due from related parties approximate their fair value due to their short-term nature. Other than noted above, the Company did not have any other assets or liabilities that were measured at fair value on a recurring basis as of April 30, 2019 or July 31, 2018.

NOTE 6 — TRADE ACCOUNTS RECEIVABLE

Trade Accounts Receivable consisted of the following:

	April 30, 2019			July 31, 2018
	(unaudited, in thousands)
Trade Accounts Receivable – Third Party	$	747		$	358
Trade Accounts Receivable – Related Party		11			11
Less Allowance for Doubtful Accounts		(86	)		(82	)
Trade Accounts Receivable, net	$	672		$	287

The current portion of deferred rental income included in Prepaid Expenses and Other Current Assets was approximately $334,000 and $88,000 as of April 30, 2019 and July 31, 2018, respectively.

The noncurrent portion of deferred rental income included in Other Assets was approximately $1.2 million and $1.0 million as of April 30, 2019 and July 31, 2018, respectively.

10

Notes to Unaudited Consolidated and Combined Financial Statements (continued)

NOTE 7 — PROPERTY AND EQUIPMENT

Property and equipment consisted of the following:

	April 30, 2019			July 31, 2018
	(unaudited, in thousands)
Building and Improvements	$	53,118		$	52,818
Land		10,412			10,412
Furniture and Fixtures		1,145			1,145
Other		255			255
Construction in Progress		1,095			1,024
Less Accumulated Depreciation		(16,844	)		(15,541	)
Total	$	49,181		$	50,113

Other property and equipment consists of furniture and fixtures, office and other equipment and miscellaneous computer hardware.

Depreciation and amortization expense pertaining to property and equipment was approximately $436,000 and $422,000 for the three months ended April 30, 2019 and 2018, respectively, and $1.3 million for each of the nine months ended April 30, 2019 and 2018, respectively.

NOTE 8 — LOSS PER SHARE

Basic net loss per share is computed by dividing net loss attributable to all classes of common stockholders of the Company by the weighted average number of shares of all classes of common stock outstanding during the applicable period. Diluted loss per shares includes potentially dilutive securities such as stock options and other convertible instruments. For the three and nine months ended April 30, 2019 and 2018 these securities have been excluded from the calculation of diluted net loss per shares because all such securities are anti-dilutive for all periods presented.

The following table summarizes the Company’s securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:

	April 30, 2019		July 31, 2018
	(unaudited)
Stock Options		573,127		626,580
Convertible Note		1,770,956		—
Total		2,344,083		626,580

In the three and nine months ended April 31, 2019 and 2018, the diluted loss per share computation equals basic loss per share because the Company had a net loss and the impact of the assumed exercise of stock options and conversion of the convertible note would have been anti-dilutive. For all periods prior to the Spin-Off, the Company utilized the number of shares distributed in the Spin-Off as the denominator for historical loss per share for each period presented.

NOTE 9 — ESTABLISHMENT OF VALUATION ALLOWANCE FOR DEFERRED TAX ASSET

Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. On the basis of this evaluation, a valuation allowance of $8.4 million was recorded to reserve for the entirety of the Company’s domestic deferred tax asset during the first quarter of fiscal 2018. The amount of the deferred tax asset considered realizable could be adjusted if estimates of future taxable income are increased.

11

Notes to Unaudited Consolidated and Combined Financial Statements (continued)

NOTE 10 — INVESTMENT IN RAFAEL PHARMACEUTICALS

Rafael Pharmaceuticals is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.

The Company owns interests/rights in Rafael Pharmaceutical through a 90%-owned non-operating subsidiary, IDT-Rafael Holdings, LLC, or IDT-Rafael Holdings. IDT-Rafael Holdings holds 36.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase ownership to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the “Warrant”). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share, subject to certain adjustments, and will expire upon the earlier of December 31, 2020, a qualified initial public offering, or liquidation event of Rafael Pharmaceuticals.

IDT-Rafael Holdings also owns 50% of CS Pharma, a non-operating entity that holds 16.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock

Howard Jonas, Chairman of the Board and Chief Executive Officer of the Company, and Chairman of the Board of Rafael Pharmaceuticals owns 10% of IDT-Rafael Holdings. Accordingly, the Company holds an effective 45% indirect interest in the assets held by CS Pharma.

IDT-Rafael Holdings also holds certain governance rights in Rafael Pharmaceuticals including appointment of directors.

The Company and its subsidiaries collectively own securities representing 51.0% of the outstanding capital stock of Rafael Pharmaceuticals and 39.5% of the capital stock on a fully diluted basis (excluding the remainder of the Warrant). 

The Series D Convertible Preferred Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the board of Rafael Pharmaceuticals, prior to any dividends to any other class of capital stock of Rafael Pharmaceuticals. In the event of any liquidation, dissolution or winding up of the Company, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution, winding up shall be distribute first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class.

The Company serves as the managing member of IDT-Rafael Holdings and IDT-Rafael Holdings serves as the managing member of CS Pharma, with broad authority to make all key decisions regarding their respective holdings. Any distributions that are made to CS Pharma from Rafael Pharmaceuticals that are in turn distributed by CS Pharma, will need to be made pro rata to all members, which would entitle IDT-Rafael Holdings to 50% (based on current ownership) of such distributions. Similarly, if IDT-Rafael Holdings were to distribute proceeds it receives from CS Pharma, it would do so on a pro rata basis, entitled the Company to 90% (based on current ownership) of such distributions.

The Company evaluated its investments in Rafael Pharmaceuticals in accordance with ASC 323, Investments - Equity Method and Joint Ventures to establish the appropriate accounting treatment for its investment and has concluded that its investment did not meet the criteria for the equity method of accounting.

Rafael Pharmaceuticals is a variable interest entity; however, the Company has determined that it is not the primary beneficiary as is does not have the power to direct the activities of Rafael Pharmaceuticals that most significantly impact Rafael Pharmaceuticals’ economic performance.

12

Notes to Unaudited Consolidated and Combined Financial Statements (continued)

Separately, Howard Jonas and Deborah Jonas jointly own $525,000 of Series C Convertible Notes of Rafael Pharmaceuticals, and The Howard S. and Deborah Jonas Foundation owns $525,000 of Series C Notes of Rafael Pharmaceuticals.

On September 19, 2017, IDT approved a compensatory arrangement with Howard Jonas related to the right held by IDT-Rafael Holdings to receive additional Rafael Pharmaceutical shares (“Bonus Shares”) upon the achievement of certain milestones. Under that arrangement, IDT and the Company transferred to Howard Jonas the contractual right to receive “Bonus Shares” for an additional 10% of the outstanding capital stock of Rafael Pharmaceuticals that was previously held by IDT-Rafael Holdings, which is contingent upon achieving certain milestones. This right was previously held by IDT-Rafael Holdings, subject to its right to transfer to recipients that IDT-Rafael Holdings, in its sole discretion, felt merit because of special efforts by such persons in assisting Rafael Pharmaceuticals and its products. IDT-Rafael Holdings distributed the rights to its members and the Company transferred the portion it received to Howard Jonas. If any of the milestones are met, the Bonus Shares are to be issued without any additional payment. Howard Jonas has the right to transfer the Bonus Shares, in his discretion, to others, including those who are instrumental to the future success of Rafael Pharmaceuticals.

NOTE 11 — RELATED PARTY TRANSACTIONS

The Company has historically maintained an intercompany balance Due to/from Related Parties that relates to cash advances for investments, loan repayments, charges for services provided to the Company by IDT and payroll costs for the Company’s personnel that were paid by IDT. This is partially offset by rental income paid to the Company by various companies under common control to IDT and charges for services provided by the Company to Rafael Pharmaceuticals for rent, accounting and other administrative expenses.  The Company’s liability at July 31, 2018 was comprised of a deposit of $864,000 from Howard Jonas, Chairman of the Board, Chief Executive Officer and controlling stockholder of the Company partially offset by amounts due from IDT and Rafael Pharmaceuticals. During the nine months ended April 30, 2019, the Company issued shares to Howard Jonas in exchange for the deposit and some prior related party balances and charges within the nine month period have been settled. At April 30, 2019, there was a balance due to related parties of approximately $44,000 and a balance due from Rafael Pharmaceuticals of $160,000. 

The change in the Company’s liability to related parties was as follows:

	Due to IDT			Due from Rafael Pharmaceuticals
	(unaudited, in thousands)
Balance at January 31, 2019	$	40		$	(40	)
Payments by IDT on behalf of the Company		52			—
Rental revenue billed to Related Parties		(473	)		—
Cash repayments, net of advances		425			—
Billings for services performed for Rafael Pharmaceuticals		—			(120	)
Balance at April 30, 2019	$	44		$	(160	)

13

Notes to Unaudited Consolidated and Combined Financial Statements (continued)

On November 15, 2018, Howard Jonas entered into an agreement to purchase a convertible note from the Company for $15.0 million. The term of the note is three years and interest will accrue on the principal amount at a rate of 6% per annum, compounded quarterly. At the option of the Company, interest on the note can be capitalized and added to principal or payable in cash. The note is convertible at the option of the holder into shares of Class B common stock at a conversion price of $8.47 per share, the closing price of the Company’s Class B common stock on the trading day before the date of the investment agreement. The initial principal amount is convertible into 1,770,956 shares of Class B common stock, and if all interest for the three-year term of the note is capitalized, the note will be convertible into 2,117,388 shares of Class B common stock. If the closing price of the Company’s Class B common stock on the NYSE American is 200% of the conversion price for at least thirty (30) consecutive days, the Company may cause conversion of the note.

At issuance, the Company recorded a debt discount of approximately $70,000 related to the beneficial conversion feature of the note and amortized approximately $10,000 of the discount in fiscal 2019 which was included in interest expense. In addition, the Company recorded $228,000 and $418,000 of interest expense for the three and nine months ended April 30, 2019 that is included in accrued expenses in the accompanying consolidated and combined statements of operations.

	April 30, 2019
Convertible Note:	(unaudited, in thousands)
Principal value of 6% convertible note at April 30, 2019, due November 15, 2021	$	15,000
Debt discount		(60	)
Total long-term carrying value of convertible note	$	14,940

NOTE 12 — INCOME TAXES

On December 22, 2017, the U.S. government enacted “An Act to Provide for Reconciliation Pursuant to Titles II and V of the Concurrent Resolution on the Budget for Fiscal Year 2018”, which is commonly referred to as “The Tax Cuts and Jobs Act” (the “Tax Act”). The Tax Act provides for comprehensive tax legislation that, among other things, reduces the U.S. federal statutory corporate tax rate from 35.0% to 21.0% effective January 1, 2018, broadens the U.S. federal income tax base, requires companies to pay a one-time repatriation tax on earnings of certain foreign subsidiaries that were previously tax deferred (“transition tax”), and creates new taxes on certain foreign sourced earnings.

The Company has completed its accounting for the income tax effects of the enactment of the Tax Act. At July 31, 2018, the Company did not have any undistributed earnings of its foreign subsidiaries. As a result, no additional income or withholding taxes were provided for, for the undistributed earnings or any additional outside basis differences inherent in the foreign entities. The Company reviewed the global intangible low taxed income (“GILTI”) and base erosion anti-abuse tax (“BEAT) that became effective August 1, 2018 and has not recorded any impact associated with either.

At July 31, 2018, the Company had available federal and state net operating loss (“NOL”) carryforwards from domestic operations of approximately $20.0 million, to offset future taxable income. The Company has no available NOLs from foreign operations available to offset future domestic taxable income. As part of the Tax Act, NOL’s generated in 2018 and later are not subject to an expiration period and are available to offset 80% of taxable income in the year in which they are utilized. The federal and state NOL carryforwards generated prior to 2018 will begin to expire in 2026. For the nine months ended April 30, 2019 the Company recorded additional losses of approximately $1.5 million from domestic operations and the possibility of future cumulative losses still exists. Accordingly, the Company has continued to maintain a valuation allowance against its net deferred tax assets and expects that the NOL’s will increase to approximately $22.1 million.

The Company anticipates that its assumptions and estimates may change as a result of future guidance and interpretation from the Internal Revenue Service, the SEC, the FASB, and various other taxing jurisdictions. In particular, the Company anticipates that the U.S. state jurisdictions will continue to determine and announce their conformity with or decoupling from the Tax Act, either in its entirety or with respect to specific provisions. Legislative and interpretive actions could result in adjustments to the Company’s provisional estimates when the accounting for the income tax effects of the Tax Act is completed.

14

Notes to Unaudited Consolidated and Combined Financial Statements (continued)

NOTE 13 — BUSINESS SEGMENT INFORMATION

The Company conducts business as two operating segments, Pharmaceuticals and Real Estate. The Company’s reportable segments are distinguished by types of service, customers and methods used to provide their services. The operating results of these business segments are regularly reviewed by the Company’s chief operating decision makers.

Beginning in the second quarter of fiscal 2018, the Pharmaceuticals segment is comprised of debt interests and a warrant to purchase equity interests in Rafael Pharmaceuticals and a majority equity interest in LipoMedix. Comparative results have been reclassified and restated as if the Pharmaceuticals segment existed for all periods presented. To date, the Pharmaceuticals segment has not generated any revenues.

The Real Estate segment consists of the Company’s real estate holdings, including the building at 520 Broad Street in Newark, New Jersey that houses the Company and certain affiliates and its associated public garage, an office/data center building in Piscataway, New Jersey and a portion of an office building in Israel.

The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Pharmaceuticals segment based primarily on research and development efforts and results of clinical trials and the Real Estate segment based primarily on income (loss) from operations. All investments in Rafael Pharmaceuticals and assets and expenses associated with LipoMedix are tracked separately in the Pharmaceuticals segment. All corporate costs are allocated to the Real Estate segment.

Operating results for the business segments of the Company are as follows:

(unaudited, in thousands)	Pharmaceuticals			Real Estate			Total
Three months ended April 30, 2019
Revenues	$	—		$	1,377		$	1,377
Loss from operations		(311	)		(1,107	)		(1,418	)
Three months ended April 30, 2018
Revenues	$	—		$	1,093		$	1,093
Loss from operations		(258	)		(473	)		(731	)

(unaudited, in thousands)	Pharmaceuticals			Real Estate			Total
Nine months ended April 30, 2019
Revenues	$	—		$	3,529		$	3,529
Loss from operations		(1,014	)	$	(2,930	)		(3,944	)
Nine months ended April 30, 2018
Revenues	$	—		$	3,157		$	3,157
Loss from operations		(631	)		(1,969	)		(2,600	)

Geographic Information

Revenues from tenants located outside of the United States were generated entirely from related parties located in Israel. Revenues from these non-United States customers as a percentage of total revenues were as follows (revenues by country are determined based on the location of the related facility):

Three Months Ended April 30,	2019			2018
	(unaudited)
Revenue from tenants located in Israel		2	%		3	%

Nine Months Ended April 30,	2019			2018
	(unaudited)
Revenue from tenants located in Israel		2	%		5	%

Net long-lived assets and total assets held outside of the United States, which are located in Israel, were as follows:

(unaudited, in thousands)	United States		Israel		Total
April 30, 2019
Long-lived assets, net	$	47,502	$	1,679	$	49,181
Total assets		139,559		3,894		143,453
July 31, 2018
Long-lived assets, net	$	48,415	$	1,698	$	50,113
Total assets		113,279		3,641		116,920

15

Notes to Unaudited Consolidated and Combined Financial Statements (continued)

NOTE 14 — COMMITMENTS AND CONTINGENCIES

Legal Proceedings

On August 21, 2018, the Company entered into a settlement agreement with a building service provider in order to avoid the risks, delays and expenses inherent in and resulting from litigation. The $100,000 settlement was included in “Selling, general and administrative” expenses in the 2018 consolidated and combined statement of operations and in “Accrued Expenses” in the accompanying consolidated balance sheets. As the Company is fully indemnified by IDT for the settlement amount, a corresponding receivable was included in “Due to Related Parties” in the accompanying consolidated balance sheets. This amount has since been repaid in the first quarter of fiscal 2019.

Under a Founders Agreement among LipoMedix and other parties, two of LipoMedix’ founders would become entitled to consulting payments in the approximate amounts of $385,000 and $358,000, respectively, upon the satisfaction of certain conditions thereto. LipoMedix believes that those conditions have not been satisfied and does not believe that they are likely to be satisfied until LipoMedix is successful in raising significant equity capital in the future.

On September 17, 2018, LipoMedix was notified of a claim initiated by one of its founders seeking payment of consulting fees in the amount of approximately $377,000 and seeking to place restrictions on LipoMedix’ bank accounts and other assets to protect his claim. LipoMedix does not believe that the individual has the right to receive any payment at the current time. LipoMedix responded to the demand for the placement of restrictions on its assets. On November 26, 2018 the court denied the request by the founder to place restrictions on the assets. LipoMedix intends to vigorously defend this matter. LipoMedix and that founder are engaged in settlement discussions.  In May 2019, LipoMedix received a letter from the other founder requesting payment of his consulting fees.

The Company may from time to time be subject to legal proceedings that may arise in the ordinary course of business. Although there can be no assurance in this regard, the Company does not expect any of those legal proceedings to have a material adverse effect on the Company’s results of operations, cash flows or financial condition.

NOTE 15 — STOCK BASED COMPENSATION

Stock Options

Options to purchase 38,710 shares of Class B common stock were exercised during the nine months ended April 30, 2019. At April 30, 2019, there was no unrecognized compensation cost related to non-vested stock options.

Pursuant to the Company’s 2018 Equity Incentive Plan, each of the three non-employee directors of the Company were granted 4,203 restricted shares of our Class B common stock in January 2019 which fully vested on the date of the grant. The fair value of the awards on the date of the grant was approximately $107,000 which was included in selling, general and administrative expense.

16

Notes to Unaudited Consolidated and Combined Financial Statements (continued)

Restricted Stock

The fair value of restricted shares of the Company’s Class B common stock is determined based on the closing price of the Company’s Class B common stock on the grant date. Share awards generally vest on a graded basis over three years of service.

A summary of the status of the Company’s grants of restricted shares of Class B common stock is presented below:

(unaudited)	Number of Non-vested Shares			Weighted-Average Grant-Date Fair Value
Outstanding at July 31, 2018		141,799		$	4.90
Granted		71,468			17.22
Vested		(60,010	)		4.90
Cancelled / Forfeited		—			—
NON-VESTED SHARES AT April 30, 2019		153,257		$	10.62

At April 30, 2019, there was $1.3 million of total unrecognized compensation cost related to non-vested stock-based compensation arrangements, which is expected to be recognized over 5 years. The total grant date fair value of shares vested in the nine months ended April 30, 2019 and 2018 was approximately $298,000 and $0, respectively.

NOTE 16 — FUTURE MINIMUM RENTS 

Certain of the Company’s properties are leased to tenants under net operating leases with initial term expiration dates ranging from 2021 to 2028. The future contractual minimum lease payments to be received (excluding operating expense reimbursements) by the Company as of April 30, 2019, under non-cancelable operating leases which expire on various dates through 2028, are as follows:

Year ending July 31,	Related Parties		Other		Total
(unaudited, in thousands)
2019	$	515	$	180	$	696
2020		1,992		1,054		3,046
2021		2,041		1,136		3,177
2022		2,078		993		3,071
2023		2,117		630		2,747
Thereafter		3,815		4,663		8,478
Total Minimum Future Rental Income	$	12,558	$	8,656	$	20,214

The Company has related party leases that expire in April 2025, for (i) an aggregate of 88,631 square feet, and which includes two parking spots per thousand square feet of space leased at 520 Broad Street, and (ii) 3,595 square feet in Israel. The annual rent is approximately $2.0 million in the aggregate. The related parties have the right to terminate the domestic leases upon four months’ notice, and upon early termination will pay a termination penalty equal to 25% of the portion of the rent due over the course of the remaining term. A related party has the right to terminate the Israeli lease upon four months’ notice. IDT has the right to lease an additional 50,000 square feet, in 25,000 foot increments, in the building located at 520 Broad Street on the same terms as their base lease, and other rights should 25,000 square feet or less remain available to lessees in the building. Upon expiration of the lease, related parties have the right to renew the leases for another five years.

17

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

On March 26, 2018, IDT Corporation, which we refer to as IDT, our former parent corporation, completed a tax-free spinoff (the “Spin-Off”) of our capital stock, through a pro rata distribution of our common stock to its stockholders of record as of the close of business on March 13, 2018 (the “Spin-Off Record Date”). As a result of the Spin-Off, each of IDT’s stockholders received: (i) one share of the Company’s Class A common stock for every two shares of IDT’s Class A common stock held on the Spin-Off Record Date, and (ii) one share of the Company’s Class B common stock for every two shares of IDT’s Class B common stock held of record on the Spin-Off Record Date. and (iii) cash in lieu of a fractional share of all classes of our common stock.

Rafael owns interests in clinical and early stage pharmaceutical companies and owns commercial real estate asset. The assets are operated as two separate lines of business. The pharmaceutical holdings include preferred equity interests and a warrant to purchase equity interest in Rafael Pharmaceuticals, Inc., or Rafael Pharma, which is a clinical stage, oncology-focused, pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells, and a majority equity interest in LipoMedix Pharmaceuticals Ltd., or LipoMedix, an oncology company based in Israel. The commercial real estate holdings consist of the building at 520 Broad Street in Newark, New Jersey that houses headquarters for the Company and affiliated entities as well third-party tenants, and an associated 800 car public garage, an office/data center building in Piscataway, New Jersey and a portion of an office building in Israel.

Results of Operations

Our business consists of two reportable segments - Pharmaceuticals and Real Estate. We evaluate the performance of our Pharmaceuticals segment based primarily on research and development efforts and results of clinical trials and our Real Estate segment based primarily on income (loss) from operations. Accordingly, the income and expense line items below (loss) income from operations are only included in the discussion of consolidated and combined results of operations.

Three and Nine Months Ended April 30, 2019 Compared to Three and Nine Months Ended April 30, 2018

Pharmaceuticals Segment

To date, the Pharmaceuticals segment has not generated any revenues. The entirety of the expenses in the Pharmaceuticals segment relate to the activities of LipoMedix. For the nine months ended April 30, 2018 expenses are our proportionate share of LipoMedix, in which we held a 38.9% interest before increasing to a majority stake during November 2017. For the nine months ended April 30, 2019, we held a 50.6% interest in LipoMedix and consolidated our majority interest in LipoMedix for the entire nine-month period.

	Three Months Ended April 30,						Change
	2019			2018			$			%
	(unaudited, in thousands)
Selling, general and administrative	$	(11	)	$	(258	)	$	247			(95.7	)%
Research and development		(300	)		—			(300	)		(100	)
Depreciation and amortization		—			—			—			—
Loss from operations	$	(311	)	$	(258	)	$	(53	)		20.5	%

18

	Nine Months Ended April 30,						Change
	2019			2018			$			%
	(unaudited, in thousands)
Selling, general and administrative	$	(64	)	$	(631	)	$	567			(89.9	)%
Research and development		(949	)		—			(949	)		(100	)
Depreciation and amortization		(1	)		—			(1	)		(100	)
Loss from operations	$	(1,014	)	$	(631	)	$	(383	)		60.7	%

Real Estate Segment

Revenues. Rental and Parking revenues increased by approximately $284,000 and $372,000 in the three and nine months ended April 30, 2019, respectively, primarily due to additional third-party tenants in 520 Broad Street having started rental payments after the start of fiscal 2019, and an increase in usage of the garage.

Selling, general and administrative expenses.  Selling, general and administrative expenses consists mainly of payroll, benefits, facilities, consulting and professional fees. The increase in selling, general and administrative expenses in the nine months ended April 31, 2019 compared to the nine months ended April 30, 2018 is primarily due to increased costs related to complying with public company requirements and costs of building maintenance and repairs.

Depreciation and amortization expenses. Depreciation and amortization expenses in the nine months ended April 30, 2019 were consistent with the expenses in the nine months ended April 30, 2018.

On January 31, 2019, there was an incident at 520 Broad Street in which one of the Company’s maintenance workers was injured. The Company has reported the incident and is cooperating with relevant authorities.

	Three Months Ended April 30,						Change
	2019			2018			$			%
	(unaudited, in thousands)
Rental – Third Party Revenue	$	588		$	400		$	188			46.9	%
Rental – Related Party Revenue		521			447			74			16.5
Parking Revenue		268			246			22			9
Selling, general and administrative		(2,048	)		(1,144	)		(904	)		79
Depreciation and amortization		(436	)		(422	)		(14	)		3.3
Loss from operations	$	(1,107	)	$	(473	)	$	(634	)		134.1	%

	Nine Months Ended April 30,						Change
	2019			2018			$			%
	(unaudited, in thousands)
Rental – Third Party Revenue	$	1,277		$	1,085		$	192			17.7	%
Rental – Related Party Revenue		1,564			1,442			122			8.5
Parking Revenue		688			630			58			9.2
Selling, general and administrative		(5,164	)		(3,850	)		(1,314	)		34.1
Depreciation and amortization		(1,295	)		(1,276	)		(19	)		1.5
Loss from operations	$	(2,930	)	$	(1,969	)	$	(961	)		48.8	%

19

Consolidated and combined operations

Our consolidated and combined income and expense line items below income from operations were as follows:

	Three Months Ended April 30,						Change
	2019			2018			$			%
	(unaudited, in thousands)
Loss from operations	$	(1,418	)	$	(731	)	$	(687	)		94	%
Interest (expense) income, net		(221	)		71			(292	)		(411	)
Net gains (loss) resulting from foreign exchange transactions		19			(28	)		47			167
Gain on sales of marketable securities, net		—			24			(24	)		(100	)
Unrealized gain on Investments – Hedge Funds		466			—			466			100
Loss before income taxes		(1,154	)		(664	)		(490	)		(74	)
Benefit from income taxes		7			5			2			39
Net Loss	$	(1,147	)	$	(659	)	$	(488	)		(74	)%
Net loss attributable to noncontrolling interests		(142	)		(128	)		(14	)		(12	)
Net loss attributable to Rafael Holdings, Inc.	$	(1,005	)	$	(531	)	$	(474	)		(89	)%

	Nine Months Ended April 30,						Change
	2019			2018			$			%
	(unaudited, in thousands)
Loss from operations	$	(3,944	)	$	(2,600	)	$	(1,344	)		52	%
Interest income, net		647			75			572			762
Net gains resulting from foreign exchange transactions		19			90			(71	)		(79	)
Net loss on equity investments		—			(104	)		104			(100	)
Gain on sales of marketable securities, net		330			24			306			1,276
Unrealized gain on Investments – Hedge Funds		414			—			414			100
Gain on disposal of bonus shares		—			246			(246	)		(100	)
Loss before income taxes		(2,534	)		(2,269	)		(265	)		12
Benefit from (provision for) income taxes		21			(8,438	)		8,459			(100	)
Net Loss	$	(2,513	)	$	(10,707	)	$	8,194			(77	)%
Net (loss) income attributable to noncontrolling interests		(6	)		304			298			(98	)
Net loss attributable to Rafael Holdings, Inc.	$	(2,507	)	$	(10,403	)	$	7,896			(76	)%

Interest income, net. Interest income, net increased in the nine months ended April 30, 2019 due to interest on the approximately $50.0 million of cash and marketable securities contributed by IDT as of the Spin-off on March 26, 2018 which was offset by interest expense on the related party convertible debt.

20

Net gain resulting from foreign exchange transactions.  Net gains resulting from foreign exchange transactions are comprised entirely from changes in movements in New Israeli Shekels relative to the U.S. Dollar.

Net loss on equity investment.  Net loss on equity investment for the nine months ended April 30, 2018 relates entirely to our proportionate share of the net loss recorded by LipoMedix, in which we held a 38.9% interest before increasing to a majority stake during November 2017. For the nine months ended April 30, 2019 we held a 50.6% interest in LipoMedix and consolidated our majority interest in LipoMedix.

Gain on sale of marketable securities and unrealized loss on investments. The company implemented ASU 2016-01 effective August 1, 2018 and no longer recognizes unrealized holding gains and losses in other comprehensive income. Realized and unrealized gains and losses are now included in net income. For the nine months ended April 30, 2019, the Company recorded a gain of approximately $330,000 on the sale of marketable securities net of unrealized losses recorded in the first quarter of fiscal 2019. The Company also recorded an unrealized gain of approximately $414,000 for the nine months ended April 30, 2019. ASU 2016-01 was not implemented for the comparable quarter in fiscal 2018.

Provision for income taxes. During the nine months ended April 30, 2019, we recorded a valuation allowance of $8.4 million for the entirety of the Company’s domestic deferred tax asset during the first quarter of fiscal 2018. We reserved for the entirety of the Company’s domestic deferred tax asset.

Net Income Attributable to Noncontrolling Interests. The change in the net income attributable to noncontrolling interests in the nine months ended April 30, 2019 compared to the similar periods in fiscal 2018 was due to the net loss attributable to the noncontrolling interests in LipoMedix in the nine months ended April 30, 2019 and the interest on the Rafael Pharmaceuticals Series D Convertible Note attributable to the noncontrolling interests in CS Pharma and IDT-Rafael Holdings.

Liquidity and Capital Resources

General

Prior to the Spin-Off, we satisfied our cash requirements primarily through intercompany debt funding from IDT. In connection with the Spin-Off, IDT transferred assets to Rafael such that, at the time of the Spin-Off, we had approximately $42.7 million in cash and cash equivalents and liquid marketable securities and approximately $3.9 million in interests in hedge funds.

As of April 30, 2019, we had cash and cash equivalents of $13.0 million. We expect our cash from operations in the next twelve months and the balance of cash and cash equivalents and liquid marketable securities that we held as of April 30, 2019 to be sufficient to meet our currently anticipated working capital, research and development, and capital expenditure requirements during the next twelve-months.

	April 30,
(unaudited, in thousands)	2019			2018
Cash flows (used in) provided by
Operating activities	$	(2,538	)	$	(1,070	)
Investing activities		(31,203	)		(136	)
Financing activities		30,854			0
Effect of exchange rates on cash and cash equivalents		53			55
(Decrease) increase in cash and cash equivalents	$	(2,834	)	$	(1,151	)

Operating Activities

Our cash flow from operations varies from year to year, depending on our operating results and the timing of operating cash receipts and payments, specifically payments of trade accounts payable. The increase in cash flows used in operating activities in the nine months ended April 30, 2019 as compared to the nine months ended April 30, 2018 related to increased accounts receivable related tenants in 520 Broad, an increase in prepaid expenses due to timing of real estate tax and insurance payments and payoff of charges due to related parties.

21

Investing Activities

Cash used in investing activities for the nine months ended April 30, 2019 related to the exercise of the portion of the warrant to purchase an equity interest of Rafael Pharmaceuticals for approximately $55.9 million offset by the net proceeds from the sale of marketable securities of approximately $25.0 million.

Financing Activities

Cash provided by financing activities for the nine months ended April 30, 2019 related to approximately $4.6 million received from the minority holder of interests in a consolidated entity, the $15.0 million convertible note received from Howard Jonas, repayment of the $3.3 million loan to Rafael Pharmaceuticals and $7.8 million received from the sale of Class B common shares to Howard Jonas.

We do not anticipate paying dividends on our common stock until we achieve sustainable profitability and retain certain minimum cash reserves. The payment of dividends in any specific period will be at the sole discretion of our Board of Directors.

Critical Accounting Policies and Estimates

We have chosen accounting policies that we believe are appropriate to accurately and fairly report our operating results and financial condition in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. We apply these accounting policies in a consistent manner. Our significant accounting policies are discussed in Note 2, “Summary of Significant Accounting Policies,” to our financial statements included in our 2018 Form 10-K.

The application of critical accounting policies requires that we make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. These estimates and assumptions are based on historical and other factors believed to be reasonable under the circumstances. We evaluate these estimates and assumptions on an ongoing basis and may retain outside consultants to assist in our evaluation. If actual results ultimately differ from previous estimates, the revisions are included in results of operations in the period in which the actual amounts become known. The critical accounting policies that involve the most significant management judgments and estimates used in preparation of our financial statements, or are the most sensitive to change from outside factors, are discussed in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of the 2018 Annual Report. There have been no material changes in our critical accounting policies and procedures during the nine months ended April 30, 2019.

Off-Balance Sheet Arrangements

We do not have any “off-balance sheet arrangements,” as defined in relevant SEC regulations that are reasonably likely to have a current or future effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources.

In connection with the Spin-Off, we and IDT entered into a tax separation agreement, which sets forth the responsibilities of IDT and us with respect to, among other things, liabilities for federal, state, local and foreign taxes for periods before and including the Spin-Off, the preparation and filing of tax returns for such periods and disputes with taxing authorities regarding taxes for such periods. IDT is generally responsible for our federal, state, local and foreign income taxes for periods before and including the Spin-Off. We are generally responsible for all other taxes relating to our business. We and IDT will each generally be responsible for managing those disputes that relate to the taxes for which each of us is responsible and, under certain circumstances, may jointly control any dispute relating to taxes for which both of us are responsible.

Item 3. Quantitative and Qualitative Disclosures About Market Risks

There have been no significant changes in our market risk exposures from those described in Item 7A of our 2018 Form 10-K.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures. Our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of April 30, 2019.

Changes in Internal Control over Financial Reporting. There were no changes in our internal control over financial reporting during the quarter ended April 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

22

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Legal proceedings in which we are involved are more fully described in Note 14 to the Consolidated and Combined Financial Statements included in Item 1 to Part I of this Quarterly Report on Form 10-Q.

Item 1A. Risk Factors

Item 1A Risk Factors contained in our 2018 Form 10-K, includes a discussion of risk factors related to investment in our common stock which is incorporated herein. There were no material changes from the risk factors associated with our business previously disclosed in Part I, Item 1A “Risk Factors” of our 2018 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults Upon Senior Securities

None

Item 4. Mine Safety Disclosures

Not applicable

Item 5. Other Information

None

23

Item 6. Exhibits

Exhibit Number	Description
31.1*	Certification of Chief Executive Officer pursuant to 17 CFR 240.13a-14(a), as adopted pursuant to §302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Chief Financial Officer pursuant to 17 CFR 240.13a-14(a), as adopted pursuant to §302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002.
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document.
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document.

* Filed or furnished herewith.

24

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Rafael Holdings, Inc.
June 5, 2019	By:	/s/ Howard S. Jonas
		Howard S. Jonas Chief Executive Officer
	By:	/s/ David Polinsky
		David Polinsky Chief Financial Officer

25

EX-31.1

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER 

PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Howard S. Jonas, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Rafael Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 5, 2019

/s/ Howard S. Jonas

Howard S. Jonas

Chief Executive Officer

EX-31.2

EXHIBIT 31.2

CERTIFICATION OF CHIEF EXECUTIVE OFFICER 

PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David Polinsky, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Rafael Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 5, 2019

/s/ David Polinsky

David Polinsky

Chief Financial Officer

EX-32.1

EXHIBIT 32.1

Certification Pursuant to
18 U.S.C. Section 1350
(as Adopted Pursuant to Section 906 of
the Sarbanes-Oxley Act Of 2002)

In connection with the Quarterly Report of Rafael Holdings, Inc. (the “Company”) on Form 10-Q for the quarter ended April 30, 2019 as filed with the Securities and Exchange Commission (the “Report”), I, Howard S. Jonas, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 5, 2019

/s/ Howard S. Jonas

Howard S. Jonas

Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Rafael Holdings, Inc. and will be retained by Rafael Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

EXHIBIT 32.2

Certification Pursuant to
18 U.S.C. Section 1350
(as Adopted Pursuant to Section 906 of
the Sarbanes-Oxley Act Of 2002)

In connection with the Quarterly Report of Rafael Holdings, Inc. (the “Company”) on Form 10-Q for the quarter ended April 30, 2019 as filed with the Securities and Exchange Commission (the “Report”), I, David Polinsky, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 5, 2019

/s/ David Polinsky

David Polinsky

Chief Financial Officer 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Rafael Holdings, Inc. and will be retained by Rafael Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Document and Entity Information - shares	9 Months Ended
	Apr. 30, 2019	Jun. 04, 2019
Entity Registrant Name	Rafael Holdings, Inc.
Entity Central Index Key	0001713863
Trading Symbol	RFL
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Document Type	10-Q
Document Period End Date	Apr. 30, 2019
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Ex Transition Period	false
Entity Emerging Growth Company	true
Class A common stock
Entity Common Stock, Shares Outstanding		787,163
Class B common stock
Entity Common Stock, Shares Outstanding		13,142,502

XML

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Apr. 30, 2019	Jul. 31, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 12,969	$ 15,803
Trade accounts receivable, net of allowance for doubtful accounts of $86 and $82 at April 30, 2019 and July 31, 2018	672	287
Marketable securities		24,701
Due from Rafael Pharmaceuticals	160	3,300
Prepaid expenses and other current assets	840	421
Total current assets	14,641	44,512
Property and equipment, net	49,181	50,113
Investments - Rafael Pharmaceuticals	70,018	13,300
Investments - Other Pharmaceuticals	2,000	2,000
Investments - Hedge Funds	4,632	4,218
Deferred income tax assets, net	24
Patents	407	324
In-process research and development	1,327	1,327
Other assets	1,223	1,126
TOTAL ASSETS	143,453	116,920
CURRENT LIABILITIES:
Trade accounts payable	755	367
Accrued expenses	203	500
Other current liabilities	19	24
Total current liabilities	977	891
Due to/from related parties	44	276
Convertible note, net of $60 discount - Related Party	14,940
Accrued interest on convertible note - Related Party	418
Other liabilities	210	188
TOTAL LIABILITIES	16,589	1,355
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Additional paid in capital	117,383	103,636
Accumulated deficit	(3,654)	(1,108)
Accumulated other comprehensive income	4,134	4,043
Total Rafael Holdings, Inc. stockholders' equity	118,002	106,697
Noncontrolling interests	8,862	8,868
TOTAL EQUITY	126,864	115,565
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	143,453	116,920
Class A common stock
STOCKHOLDERS' EQUITY
Common stock value	8	8
Class B common stock
STOCKHOLDERS' EQUITY
Common stock value	$ 131	$ 118

XML

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Apr. 30, 2019	Jul. 31, 2018
Allowance for doubtful accounts	$ 86	$ 82
Convertible note net of discount	$ 60
Class A common stock
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	35,000,000	35,000,000
Common stock, shares issued	787,163	787,163
Common stock, shares outstanding	787,163	787,163
Class B common stock
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	13,139,333	11,762,346
Common stock, shares outstanding	13,139,333	11,762,346

XML

Consolidated and Combined Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
REVENUES:
Rental - Third Party	$ 588	$ 400	$ 1,277	$ 1,085
Rental - Related Party	521	447	1,564	1,442
Parking	268	246	688	630
Total Revenue	1,377	1,093	3,529	3,157
COSTS AND EXPENSES:
Selling, general and administrative	2,059	1,402	5,228	4,481
Research and development	300		949
Depreciation and amortization	436	422	1,296	1,276
Loss from operations	(1,418)	(731)	(3,944)	(2,600)
Interest (expense) income net	(221)	71	647	75
Net gain (loss) resulting from foreign exchange transactions	19	(28)	19	90
Net loss on equity investments				(104)
Gain on sales of marketable securities, net		24	330	24
Unrealized gain on investments – Hedge Funds	466		414
Gain on disposal of bonus shares				246
Loss before income taxes	(1,154)	(664)	(2,534)	(2,269)
Benefit from (provision for) income taxes	7	5	21	(8,438)
Net Loss	(1,147)	(659)	(2,513)	(10,707)
Net loss attributable to noncontrolling interests	(142)	(128)	(6)	(304)
Net loss attributable to Rafael Holdings, Inc.	(1,005)	(531)	(2,507)	(10,403)
OTHER COMPREHENSIVE LOSS
Net Loss	(1,147)	(659)	(2,513)	(10,707)
Unrealized loss on marketable securities		(311)		(311)
Foreign currency translation adjustments	(54)	(85)	(52)	(10)
Total Comprehensive Loss	(1,201)	(1,055)	(2,565)	(11,028)
Comprehensive (loss) income attributable to noncontrolling interests	(18)	(29)	5	(29)
Total Comprehensive Loss attributable to Rafael Holdings, Inc.	$ (1,183)	$ (1,026)	$ (2,570)	$ (10,999)
Loss Per Share attributable to Rafael Holdings Inc. common shareholders:
Basic and diluted	$ (0.07)	$ (0.04)	$ (0.19)	$ (0.83)
Weighted average number of shared used in calculation of loss per share:
Basic and diluted	13,924,691	12,541,998	13,055,037	12,541,998

XML

Consolidated and Combined Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018
Operating activities
Net loss	$ (2,513)	$ (10,707)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,296	1,276
Deferred income taxes	(24)	8,851
Interest income on Rafael Pharmaceuticals Series D Convertible Note	(848)
Net gain on sale of marketable securities	(330)	(24)
Unrealized gain on investments - Hedge Funds	(414)
Provision for doubtful accounts	86
Realized gain on disposal of bonus shares		(246)
Non-cash compensation	269	616
Amortization of debt discount	11
Interest in the equity of investments		(80)
Change in assets and liabilities:
Trade accounts receivable	(471)	(142)
Other current assets and prepaid expenses	(419)	(392)
Other assets	(180)	(355)
Accounts payable and accrued expenses	91	223
Other current liabilities	(5)	(8)
Due to/from related parties	473	(386)
Accrued interest – Related Party	418
Other liabilities	22
Net cash used in operating activities	(2,538)	(1,070)
Investing activities
Purchases of property and equipment	(364)	(572)
Proceeds from sale and maturity of marketable securities, net	25,031	436
Investment in Rafael Pharmaceuticals	(55,870)
Net cash used in investing activities	(31,203)	(136)
Financing activities
Contribution from noncontrolling interest of consolidated entity	4,587
Repayment of Due from Rafael Pharmaceuticals	3,300
Proceeds from exercise of options	190
Proceed from sale of Class B Common shares to Related Party	7,777
Proceeds from issuance of convertible note payable - Related Party	15,000
Net cash provided by financing activities	30,854
Effect of exchange rate changes on cash and cash equivalents	53	55
Net decrease in cash and cash equivalents	(2,834)	(1,151)
Cash and cash equivalents at beginning of period	15,803	11,756
Cash and cash equivalents at end of period	12,969	10,605
Supplemental Schedule of Non-Cash Investing and Financing Activities
Adoption effect of ASU 2016-01	39
Beneficial conversion feature of convertible debt – Related Party	71
Series D Convertible Note and accrued interest converted to Series D Preferred Stock	10,848
Related Party deposit utilized to purchase Class B Common Stock	864
Cash payments made for interest & taxes

XML

Consolidated and Combined Statements of Shareholder's Equity (Unaudited) - USD ($) $ in Thousands	Common Stock, Series A	Common Stock, Series B	Group Equity	Additional Paid - in Capital	Accumulated Deficit	Accumulated other comprehensive income	Noncontrolling interests	Total
Balance at Jul. 31, 2017			$ 50,426			$ 2,316	$ 9,335	$ 62,077
Balance, shares at Jul. 31, 2017
Acquisition of LipoMedix							559	559
Distribution of Rafael Pharmaceuticals Bonus Shares from IDT-Rafael Holdings to Rafael Holdings and Howard S. Jonas							(40)	(40)
Incorporation of Company, Capital contribution from IDT and share distribution on Spin-Off	$ 8	$ 118	(40,215)	103,499				63,410
Incorporation of Company, Capital contribution from IDT and share distribution on Spin-Off, shares	787,163	11,754,835
Stock Based Compensation				10				10
Unrealized Loss on Available-for-Sale Securities						(311)		(311)
Foreign currency translation adjustments						(7)	(41)	(48)
Net Loss			(10,211)		(192)		(304)	(10,707)
Balance at Apr. 30, 2018	$ 8	$ 118		103,509	(192)	1,998	9,509	114,950
Balance, shares at Apr. 30, 2018	787,163	11,754,835
Balance at Jan. 31, 2018			40,554			2,394	9,678	52,626
Balance, shares at Jan. 31, 2018
Incorporation of Company, Capital contribution from IDT and share distribution on Spin-Off	$ 8	$ 118	(40,215)	103,499				63,410
Incorporation of Company, Capital contribution from IDT and share distribution on Spin-Off, shares	787,163	11,754,835
Stock Based Compensation				10				10
Unrealized Loss on Available-for-Sale Securities						(311)		(311)
Foreign currency translation adjustments						(85)	(41)	(126)
Net Loss			(339)		(192)		(128)	(659)
Balance at Apr. 30, 2018	$ 8	$ 118		103,509	(192)	1,998	9,509	114,950
Balance, shares at Apr. 30, 2018	787,163	11,754,835
Balance at Jul. 31, 2018	$ 8	$ 118		103,636	(1,108)	4,043	8,868	115,565
Balance, shares at Jul. 31, 2018	787,163	11,762,346
Adoption effect of ASU 2016-01					(39)	39
Stock Based Compensation				151				151
Stock Options Exercised				190				190
Stock Options Exercised, shares		38,710
Restricted Stock Units issued		$ 1		11				12
Restricted Stock Units issued, shares		71,468
Stock Based Compensation to Board of Directors				107				107
Stock Based Compensation to Board of Directors, shares		12,609
Purchase of Class B Common Shares		$ 12		8,630				8,642
Purchase of Class B Common Shares, shares		1,254,200
Debt Discount on convertible debt				71				71
Capital Contribution from noncontrolling interest				4,587				4,587
Foreign currency translation adjustments						52		52
Net Loss					(2,507)		(6)	(2,513)
Balance at Apr. 30, 2019	$ 8	$ 131		117,383	(3,654)	4,134	8,862	126,864
Balance, shares at Apr. 30, 2019	787,163	13,139,333
Balance at Jan. 31, 2019	$ 8	$ 131		117,258	(2,649)	4,080	9,004	127,832
Balance, shares at Jan. 31, 2019	787,163	13,133,069
Stock Based Compensation				91				91
Stock Based Compensation, shares		750
Stock Options Exercised				27				27
Stock Options Exercised, shares		5,514
Restricted Stock Units issued				7				7
Foreign currency translation adjustments						54		54
Net Loss					(1,005)		(142)	(1,147)
Balance at Apr. 30, 2019	$ 8	$ 131		$ 117,383	$ (3,654)	$ 4,134	$ 8,862	$ 126,864
Balance, shares at Apr. 30, 2019	787,163	13,139,333

XML

Description of Business

9 Months Ended

Apr. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

DESCRIPTION OF BUSINESS

NOTE 1 — DESCRIPTION OF BUSINESS

Rafael Holdings, Inc., (“Rafael Holdings” or “the Company”), a Delaware corporation, owns interests in clinical pharmaceutical companies and owns commercial real estate assets. The assets are operated as two separate lines of business. The pharmaceutical holdings include preferred equity interests and a warrant to purchase equity interests in Rafael Pharmaceuticals, Inc., or Rafael Pharma, which is a clinical stage, oncology-focused, pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells, and a majority equity interest in LipoMedix Pharmaceuticals Ltd., or LipoMedix, an oncology company based in Israel. The commercial real estate holdings consist of the building at 520 Broad Street in Newark, New Jersey that houses headquarters for the Company, affiliated entities as well as third-party tenants, and an associated 800-car public garage, an office/data center building in Piscataway, New Jersey and a portion of a building in Israel.

On March 26, 2018, IDT Corporation, or IDT, the former parent corporation of the Company, completed a tax-free spinoff (the “Spin-Off”) of the Company’s capital stock, through a pro rata distribution of common stock to its stockholders of record as of the close of business on March 13, 2018.

The “Company” in these financial statements refers to Rafael Holdings on a consolidated basis from the date of the Spin-Off and on a combined basis from the date prior to the Spin-Off as if Rafael Holdings existed and owned the above interests in all periods presented.

All significant intercompany accounts and transactions have been eliminated in consolidation or combination.

XML

Summary of Significant Accounting Policies

9 Months Ended

Apr. 30, 2019

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited consolidated and combined financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included. Certain amounts in the prior period financial statements have been reclassified to conform with the current period presentation. These reclassifications had no effect on previously reported losses, total assets or stockholders equity.

The Company's fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated (e.g., fiscal 2019 refers to the fiscal year ending July 31, 2019).

Operating results for the three and nine months ended April 30, 2019 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2019. The balance sheet at July 31, 2018 has been derived from the Company's audited consolidated and combined financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these condensed financial statements should be read in conjunction with the Company's audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended July 31, 2018, or the 2018 Form 10-K, as filed with the U.S. Securities and Exchange Commission ("SEC").

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates.

Revenue Recognition

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update, ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606) or ASU 2014-09. The objective of the ASU is to establish a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers, which supersedes most of the existing revenue recognition guidance, including industry-specific guidance. The core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying the ASU, companies will perform a five-step analysis of transactions to determine when and how revenue is recognized. The five-step analysis consists of the following: (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations in the contract and (v) recognizing revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 applies to all contracts with customers except those that are within the scope of other topics in the FASB's ASC. The Company adopted ASU 2014-09 effective August 1, 2018 using the modified retrospective approach. The Company reviewed all contracts that were not completed as of August 1, 2018 and the adoption did not have a material impact on the Company's consolidated financial statements.

The Company disaggregates its revenue by source within its consolidated and combined statements of operations. As an owner and operator of real estate, the Company derives the majority of its revenue from leasing space to tenants at its properties. As a result, the majority of the Company's revenue is accounted for pursuant to ASC 840 Leases or ASC 840 and is reflected within Rental Revenue in the consolidated and combined statements of operations. In addition, the Company earns revenue from recoveries from tenants, consisting of amounts due from tenants for common area maintenance, real estate taxes and other recoverable costs. Revenue from recoveries from tenants is recognized under the guidance within ASC 840 until the adoption of ASC 842, Leases in 2019 at which time it may fall within the guidance under Topic 606.

Contractual rental revenue is reported on a straight-line basis over the terms of the respective leases. Accrued rental income, included within Other Assets on the consolidated balance sheets, represents cumulative rental income earned in excess of rent payments received pursuant to the terms of the individual lease agreements. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent payments or parking customers to pay amounts due.

The Company also earns revenue from parking which is derived primarily from monthly and transient daily parking. In addition, the Company has certain lease arrangements for parking accounted for under the guidance in ASC 840. The monthly and transient daily parking revenue falls within the scope of ASC 606 and is accounted for at the point in time when control of the goods or services transfers to the customer and the Company's performance obligation is satisfied, consistent with the Company's previous accounting.

Recently Issued Accounting Pronouncements Not Yet Adopted

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of reviewing all contracts with suppliers, vendors, customers and other outside parties to identify whether such contracts contain an embedded lease as defined under the new guidance and whether there will be any impact of the pending adoption of the new standard on its consolidated financial statements. The Company intends to adopt the standard on August 1, 2019.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, that changes the impairment model for most financial assets and certain other instruments. For receivables, loans and other instruments, entities will be required to use a new forward-looking "expected loss" model that generally will result in the earlier recognition of allowance for losses. For available-for-sale debt securities with unrealized losses, entities will measure credit losses in a manner similar to current practice, except the losses will be recognized as allowances instead of reductions in the amortized cost of the securities. In addition, an entity will have to disclose significantly more information about allowances, credit quality indicators and past due securities. The new standard is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years and will be applied as a cumulative-effect adjustment to retained earnings. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and intends to adopt the standard on August 1, 2020.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash or ASU 2016-18. The new guidance is intended to reduce diversity in practice by adding or clarifying guidance on classification and presentation of changes in restricted cash on the statement of cash flows. ASU 2016-18 is effective for annual and interim periods beginning after December 15, 2017. The amendments in this Statement are required to be applied retrospectively to all periods presented. The Company adopted this guidance retrospectively on August 1, 2018 with no material impact on the Company's financial position, results of operations or cash flows. On a prospective basis, ASU 2016-18 will only impact the Company's financial position and cash flows to the extent it has restricted cash.

Recently Adopted Accounting Pronouncements

In January 2016, the FASB issued ASU 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which required us to prospectively record changes in the fair value of our equity investments, except for those accounted for under the equity method, in net income instead of in accumulated other comprehensive income.  The Company implemented ASU 2016-01 in the first quarter of fiscal 2019 effective August 1, 2018. A cumulative-effect adjustment was recorded as of August 1, 2018 to reclassify approximately $39,000 of unrealized loss on equity securities from accumulated other comprehensive income to retained earnings resulting in prior-periods no longer being comparable.

SEC Disclosure Update and Simplification

In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018. The first presentation of the changes in shareholders' equity in accordance with the new guidance is included in this Quarterly Report.

XML

Investment in LipoMedix

9 Months Ended

Apr. 30, 2019

Business Combinations [Abstract]

INVESTMENT IN LIPOMEDIX

NOTE 3 — INVESTMENT IN LIPOMEDIX

LipoMedix is a development-stage, privately held Israeli company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery.

The Company holds 50.6% of the issued and outstanding ordinary shares of LipoMedix and has consolidated this investment from the second quarter of fiscal 2018.

In April 2019, the Company provided no-interest bridge financing of $250,000 to LipoMedix (the "2019 Bridge Note"). The 2019 Bridge Note is automatically convertible into shares of LipoMedix as follows: (i) upon an issuance of an aggregate $2.0 million of additional equity securities (excluding the conversion of the Bridge Notes); or (ii) upon a liquidation or dissolution of LipoMedix or a sale of LipoMedix or its assets.  If converted, the 2019 Bridge Note will be converted into shares of the most senior class of equity of LipoMedix then issued.  If converted upon an equity financing, the 2019 Bridge Note will be converted at a conversion price per share that is equal to 75% of the price paid in the equity offering. If converted upon a liquidation or sale event, the 2019 Bridge Note will be converted at a conversion price per share that is equal to 75% of the per share distribution received by LipoMedix equity holders in connection with the event, or, if greater the Company will receive a payment equal to the 2019 Bridge Note ($250,000).  If none of such events occurs prior to September 28, 2019, the 2019 Bridge Note will be converted into the most senior class of shares LipoMedix has then issued at a conversion price per share equal to $0.53 (calculated on the basis of LipoMedix's pre-money valuation of $5.0 million).

On July 2018, the Company provided no-interest bridge financing of $875,000 to LipoMedix (the "2018 Bridge Note"). The 2018 Bridge Note is convertible into shares of LipoMedix as follows: (i) upon an issuance of an aggregate $2.0 million of additional equity securities (excluding the conversion of the 2018 Bridge Note) (the "Financing"), the 2018 Bridge Note amount shall be converted into shares of LipoMedix of the same class and series with the same rights, preferences and privileges as shall be issued in the Financing at a conversion price per share equal to 75% or the lowest price per share paid by the investor(s) in the Financing; (ii) upon a Distribution Event (as defined in the Founder's Agreement among LipoMedix and certain of its founders), the 2018 Bridge Note shall be converted into shares of the most senior class of shares of LipoMedix then issued, at a conversion price per share that is equal to 75% of the per share distribution received by LipoMedix equity holders in connection with the Distribution Event, or the Company shall be entitled to receive a redemption payment equal to the 2018 Bridge Note ($875,000); (iii) if neither a Financing nor Distribution Event occurs prior to January 6, 2020 (18 months following the effective date of the 2018 Bridge Note), the 2018 Bridge Note will be converted into the most senior class of shares LipoMedix has then issued at a conversion price per share equal to $0.53 (calculated on the basis of LipoMedix's pre-money valuation of $5.0 million, divided by its fully diluted share capital as of July 6, 2018).

XML

Marketable Securities

9 Months Ended

Apr. 30, 2019

Investments, Debt and Equity Securities [Abstract]

MARKETABLE SECURITIES

NOTE 4 — MARKETABLE SECURITIES

During fiscal 2019, all marketable securities held by the Company were liquidated in connection with the partial exercise of the Rafael Pharmaceuticals warrant, see Note 10. There were no marketable securities held by the Company as of April 30, 2019.

Proceeds from maturities and sales of available-for-sale securities were approximately $0 and $25.0 million for the three and nine months ended April 30, 2019 and $436,000 for each of the three and nine months ended April 30, 2018, respectively. The net realized gain that was included in earnings as a result of sales was approximately $0 and $330,000 for the three and nine months ended April 30, 2019, respectively, and $24,000 for each of the three and nine months ended April 30, 2018. The Company uses the specific identification method in computing the gross realized gains and gross realized losses on the sales of marketable securities.

XML

Fair Value Measurments

9 Months Ended

Apr. 30, 2019

Fair Value Disclosures [Abstract]

FAIR VALUE MEASURMENTS

NOTE 5 — FAIR VALUE MEASURMENTS

The Fair Value Measurements and Disclosures topic of the FASB ASC requires disclosures about how fair value is determined for assets and liabilities and a hierarchy for which these assets and liabilities must be grouped is established, based on significant levels of inputs as follows:

Level 1 quoted prices in active markets for identical assets or liabilities;

Level 2 quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability; or

Level 3 unobservable inputs for the asset or liability, such as discounted cash flow models or valuations.

The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The following is a listing of the Company’s assets required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of April 30, 2019 and July 31, 2018:

	April 30, 2019
	Level 1		Level 2		Level 3		Total
Available-for-sale securities:	(unaudited, in thousands)
Hedge Funds	$	—	$	—	$	4,632	$	4,632
Total	$	—	$	—	$	4,632	$	4,632

	July 31, 2018
	Level 1		Level 2		Level 3		Total
Available-for-sale securities:	(unaudited, in thousands)
Marketable Securities	$	10,755	$	13,946	$	—	$	24,701
Hedge Funds		—		—		4,218		4,218
Rafael Pharmaceuticals convertible promissory notes		—		—		7,900		7,900
Total	$	10,755	$	13,946	$	12,118	$	36,819

At April 30, 2019 and July 31, 2018, the Company did not have any liabilities measured at fair value on a recurring basis.

At July 31, 2018, the fair value of the Rafael Pharmaceuticals Series D Convertible Note, (the “Series D Note”) was classified as Level 3, was estimated based on a valuation of Rafael Pharmaceuticals by reference to recent transactions in its securities, the Series D Note investment, as well as utilizing a discounted cash flow technique under the Income Approach and other factors that could not be corroborated by the market. The Series D Note was converted into shares of Series D Convertible Preferred Stock of Rafael Pharmaceuticals in January 2019.

The following table summarizes the change in the balance of the Company’s assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3).

	Three Months Ended April 31,				Nine Months Ended April 31,
	2019		2018		2019			2018
	(unaudited, in thousands)
Balance, beginning of period	$	4,166	$	6,300	$	12,118		$	6,300
Conversion of Rafael Pharmaceuticals Series D Convertible Note		—		—		(7,900	)		—
Total gains included in earnings		466		—		414			—
Balance, end of period	$	4,632	$	6,300	$	4,632		$	6,300

Prior to the Spin-Off, IDT contributed a $2.0 million investment in securities of another entity that are not liquid, which were included in “Investments – Other Pharmaceuticals” in the accompanying consolidated balance sheets. The investment is accounted for using the cost method; therefore, this investment is not measured at fair value.

Fair Value of Other Financial Instruments

The estimated fair value of the Company’s other financial instruments was determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting these data to develop estimates of fair value. Consequently, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange.

Cash and cash equivalents, prepaid expense and other current assets, and other current liabilities. At April 30, 2019 and July 31, 2018, the carrying amount of these assets and liabilities approximated fair value because of the short period of time to maturity. The fair value estimates for cash and cash equivalents were classified as Level 1 and other current assets, and other current liabilities were classified as Level 2 of the fair value hierarchy.

Other assets and other liabilities. At April 30, 2019 and July 31, 2018, the carrying amount of these assets and liabilities approximated fair value. The fair values were estimated based on the Company’s assumptions, which were classified as Level 3 of the fair value hierarchy.

The Company’s financial instruments include trade accounts receivable, trade accounts payable, and due from related parties. The recorded carrying amount of trade accounts receivable, trade accounts payable and due from related parties approximate their fair value due to their short-term nature. Other than noted above, the Company did not have any other assets or liabilities that were measured at fair value on a recurring basis as of April 30, 2019 or July 31, 2018.

XML

Trade Accounts Receivable

9 Months Ended

Apr. 30, 2019

Receivables [Abstract]

TRADE ACCOUNTS RECEIVABLE

NOTE 6 — TRADE ACCOUNTS RECEIVABLE

Trade Accounts Receivable consisted of the following:

	April 30, 2019			July 31, 2018
	(unaudited, in thousands)
Trade Accounts Receivable – Third Party	$	747		$	358
Trade Accounts Receivable – Related Party		11			11
Less Allowance for Doubtful Accounts		(86	)		(82	)
Trade Accounts Receivable, net	$	672		$	287

The current portion of deferred rental income included in Prepaid Expenses and Other Current Assets was approximately $334,000 and $88,000 as of April 30, 2019 and July 31, 2018, respectively.

The noncurrent portion of deferred rental income included in Other Assets was approximately $1.2 million and $1.0 million as of April 30, 2019 and July 31, 2018, respectively.

XML

Property and Equipment

9 Months Ended

Apr. 30, 2019

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 7 — PROPERTY AND EQUIPMENT

Property and equipment consisted of the following:

	April 30, 2019			July 31, 2018
	(unaudited, in thousands)
Building and Improvements	$	53,118		$	52,818
Land		10,412			10,412
Furniture and Fixtures		1,145			1,145
Other		255			255
Construction in Progress		1,095			1,024
Less Accumulated Depreciation		(16,844	)		(15,541	)
Total	$	49,181		$	50,113

Other property and equipment consists of furniture and fixtures, office and other equipment and miscellaneous computer hardware.

Depreciation and amortization expense pertaining to property and equipment was approximately $436,000 and $422,000 for the three months ended April 30, 2019 and 2018, respectively, and $1.3 million for each of the nine months ended April 30, 2019 and 2018, respectively.

XML

Loss Per Share

9 Months Ended

Apr. 30, 2019

Loss Per Share [Abstract]

LOSS PER SHARE

NOTE 8 — LOSS PER SHARE

Basic net loss per share is computed by dividing net loss attributable to all classes of common stockholders of the Company by the weighted average number of shares of all classes of common stock outstanding during the applicable period. Diluted loss per shares includes potentially dilutive securities such as stock options and other convertible instruments. For the three and nine months ended April 30, 2019 and 2018 these securities have been excluded from the calculation of diluted net loss per shares because all such securities are anti-dilutive for all periods presented.

The following table summarizes the Company’s securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:

	April 30, 2019		July 31, 2018
	(unaudited)
Stock Options		573,127		626,580
Convertible Note		1,770,956		—
Total		2,344,083		626,580

In the three and nine months ended April 31, 2019 and 2018, the diluted loss per share computation equals basic loss per share because the Company had a net loss and the impact of the assumed exercise of stock options and conversion of the convertible note would have been anti-dilutive. For all periods prior to the Spin-Off, the Company utilized the number of shares distributed in the Spin-Off as the denominator for historical loss per share for each period presented.

XML

Establishment of Valuation Allowance for Deferred Tax Asset

9 Months Ended

Apr. 30, 2019

Establishment of Valuation Allowance for Deferred Tax Asset [Abstract]

ESTABLISHMENT OF VALUATION ALLOWANCE FOR DEFERRED TAX ASSET

NOTE 9 — ESTABLISHMENT OF VALUATION ALLOWANCE FOR DEFERRED TAX ASSET

Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. On the basis of this evaluation, a valuation allowance of $8.4 million was recorded to reserve for the entirety of the Company's domestic deferred tax asset during the first quarter of fiscal 2018. The amount of the deferred tax asset considered realizable could be adjusted if estimates of future taxable income are increased.

XML

Investment in Rafael Pharmaceuticals

9 Months Ended

Apr. 30, 2019

Schedule of Investments [Abstract]

INVESTMENT IN RAFAEL PHARMACEUTICALS

NOTE 10 — INVESTMENT IN RAFAEL PHARMACEUTICALS

Rafael Pharmaceuticals is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.

The Company owns interests/rights in Rafael Pharmaceutical through a 90%-owned non-operating subsidiary, IDT-Rafael Holdings, LLC, or IDT-Rafael Holdings. IDT-Rafael Holdings holds 36.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase ownership to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the “Warrant”). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share, subject to certain adjustments, and will expire upon the earlier of December 31, 2020, a qualified initial public offering, or liquidation event of Rafael Pharmaceuticals.

IDT-Rafael Holdings also owns 50% of CS Pharma, a non-operating entity that holds 16.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock

Howard Jonas, Chairman of the Board and Chief Executive Officer of the Company, and Chairman of the Board of Rafael Pharmaceuticals owns 10% of IDT-Rafael Holdings. Accordingly, the Company holds an effective 45% indirect interest in the assets held by CS Pharma.

IDT-Rafael Holdings also holds certain governance rights in Rafael Pharmaceuticals including appointment of directors.

The Company and its subsidiaries collectively own securities representing 51.0% of the outstanding capital stock of Rafael Pharmaceuticals and 39.5% of the capital stock on a fully diluted basis (excluding the remainder of the Warrant). 

The Series D Convertible Preferred Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the board of Rafael Pharmaceuticals, prior to any dividends to any other class of capital stock of Rafael Pharmaceuticals. In the event of any liquidation, dissolution or winding up of the Company, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution, winding up shall be distribute first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class.

The Company serves as the managing member of IDT-Rafael Holdings and IDT-Rafael Holdings serves as the managing member of CS Pharma, with broad authority to make all key decisions regarding their respective holdings. Any distributions that are made to CS Pharma from Rafael Pharmaceuticals that are in turn distributed by CS Pharma, will need to be made pro rata to all members, which would entitle IDT-Rafael Holdings to 50% (based on current ownership) of such distributions. Similarly, if IDT-Rafael Holdings were to distribute proceeds it receives from CS Pharma, it would do so on a pro rata basis, entitled the Company to 90% (based on current ownership) of such distributions.

The Company evaluated its investments in Rafael Pharmaceuticals in accordance with ASC 323, Investments - Equity Method and Joint Ventures to establish the appropriate accounting treatment for its investment and has concluded that its investment did not meet the criteria for the equity method of accounting.

Rafael Pharmaceuticals is a variable interest entity; however, the Company has determined that it is not the primary beneficiary as is does not have the power to direct the activities of Rafael Pharmaceuticals that most significantly impact Rafael Pharmaceuticals’ economic performance.

Separately, Howard Jonas and Deborah Jonas jointly own $525,000 of Series C Convertible Notes of Rafael Pharmaceuticals, and The Howard S. and Deborah Jonas Foundation owns $525,000 of Series C Notes of Rafael Pharmaceuticals.

On September 19, 2017, IDT approved a compensatory arrangement with Howard Jonas related to the right held by IDT-Rafael Holdings to receive additional Rafael Pharmaceutical shares (“Bonus Shares”) upon the achievement of certain milestones. Under that arrangement, IDT and the Company transferred to Howard Jonas the contractual right to receive “Bonus Shares” for an additional 10% of the outstanding capital stock of Rafael Pharmaceuticals that was previously held by IDT-Rafael Holdings, which is contingent upon achieving certain milestones. This right was previously held by IDT-Rafael Holdings, subject to its right to transfer to recipients that IDT-Rafael Holdings, in its sole discretion, felt merit because of special efforts by such persons in assisting Rafael Pharmaceuticals and its products. IDT-Rafael Holdings distributed the rights to its members and the Company transferred the portion it received to Howard Jonas. If any of the milestones are met, the Bonus Shares are to be issued without any additional payment. Howard Jonas has the right to transfer the Bonus Shares, in his discretion, to others, including those who are instrumental to the future success of Rafael Pharmaceuticals.

XML

Related Party Transactions

9 Months Ended

Apr. 30, 2019

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

NOTE 11 — RELATED PARTY TRANSACTIONS

The Company has historically maintained an intercompany balance Due to/from Related Parties that relates to cash advances for investments, loan repayments, charges for services provided to the Company by IDT and payroll costs for the Company’s personnel that were paid by IDT. This is partially offset by rental income paid to the Company by various companies under common control to IDT and charges for services provided by the Company to Rafael Pharmaceuticals for rent, accounting and other administrative expenses.  The Company’s liability at July 31, 2018 was comprised of a deposit of $864,000 from Howard Jonas, Chairman of the Board, Chief Executive Officer and controlling stockholder of the Company partially offset by amounts due from IDT and Rafael Pharmaceuticals. During the nine months ended April 30, 2019, the Company issued shares to Howard Jonas in exchange for the deposit and some prior related party balances and charges within the nine month period have been settled. At April 30, 2019, there was a balance due to related parties of approximately $44,000 and a balance due from Rafael Pharmaceuticals of $160,000. 

The change in the Company’s liability to related parties was as follows:

	Due to IDT			Due from Rafael Pharmaceuticals
	(unaudited, in thousands)
Balance at January 31, 2019	$	40		$	(40	)
Payments by IDT on behalf of the Company		52			—
Rental revenue billed to Related Parties		(473	)		—
Cash repayments, net of advances		425			—
Billings for services performed for Rafael Pharmaceuticals		—			(120	)
Balance at April 30, 2019	$	44		$	(160	)

On November 15, 2018, Howard Jonas entered into an agreement to purchase a convertible note from the Company for $15.0 million. The term of the note is three years and interest will accrue on the principal amount at a rate of 6% per annum, compounded quarterly. At the option of the Company, interest on the note can be capitalized and added to principal or payable in cash. The note is convertible at the option of the holder into shares of Class B common stock at a conversion price of $8.47 per share, the closing price of the Company’s Class B common stock on the trading day before the date of the investment agreement. The initial principal amount is convertible into 1,770,956 shares of Class B common stock, and if all interest for the three-year term of the note is capitalized, the note will be convertible into 2,117,388 shares of Class B common stock. If the closing price of the Company’s Class B common stock on the NYSE American is 200% of the conversion price for at least thirty (30) consecutive days, the Company may cause conversion of the note.

At issuance, the Company recorded a debt discount of approximately $70,000 related to the beneficial conversion feature of the note and amortized approximately $10,000 of the discount in fiscal 2019 which was included in interest expense. In addition, the Company recorded $228,000 and $418,000 of interest expense for the three and nine months ended April 30, 2019 that is included in accrued expenses in the accompanying consolidated and combined statements of operations.

	April 30, 2019
Convertible Note:	(unaudited, in thousands)
Principal value of 6% convertible note at April 30, 2019, due November 15, 2021	$	15,000
Debt discount		(60	)
Total long-term carrying value of convertible note	$	14,940

XML

Income Taxes

9 Months Ended

Apr. 30, 2019

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 12 — INCOME TAXES

On December 22, 2017, the U.S. government enacted “An Act to Provide for Reconciliation Pursuant to Titles II and V of the Concurrent Resolution on the Budget for Fiscal Year 2018”, which is commonly referred to as “The Tax Cuts and Jobs Act” (the “Tax Act”). The Tax Act provides for comprehensive tax legislation that, among other things, reduces the U.S. federal statutory corporate tax rate from 35.0% to 21.0% effective January 1, 2018, broadens the U.S. federal income tax base, requires companies to pay a one-time repatriation tax on earnings of certain foreign subsidiaries that were previously tax deferred (“transition tax”), and creates new taxes on certain foreign sourced earnings.

The Company has completed its accounting for the income tax effects of the enactment of the Tax Act. At July 31, 2018, the Company did not have any undistributed earnings of its foreign subsidiaries. As a result, no additional income or withholding taxes were provided for, for the undistributed earnings or any additional outside basis differences inherent in the foreign entities. The Company reviewed the global intangible low taxed income (“GILTI”) and base erosion anti-abuse tax (“BEAT) that became effective August 1, 2018 and has not recorded any impact associated with either.

At July 31, 2018, the Company had available federal and state net operating loss (“NOL”) carryforwards from domestic operations of approximately $20.0 million, to offset future taxable income. The Company has no available NOLs from foreign operations available to offset future domestic taxable income. As part of the Tax Act, NOL’s generated in 2018 and later are not subject to an expiration period and are available to offset 80% of taxable income in the year in which they are utilized. The federal and state NOL carryforwards generated prior to 2018 will begin to expire in 2026. For the nine months ended April 30, 2019 the Company recorded additional losses of approximately $1.5 million from domestic operations and the possibility of future cumulative losses still exists. Accordingly, the Company has continued to maintain a valuation allowance against its net deferred tax assets and expects that the NOL’s will increase to approximately $22.1 million.

The Company anticipates that its assumptions and estimates may change as a result of future guidance and interpretation from the Internal Revenue Service, the SEC, the FASB, and various other taxing jurisdictions. In particular, the Company anticipates that the U.S. state jurisdictions will continue to determine and announce their conformity with or decoupling from the Tax Act, either in its entirety or with respect to specific provisions. Legislative and interpretive actions could result in adjustments to the Company’s provisional estimates when the accounting for the income tax effects of the Tax Act is completed.

XML

Business Segment Information

9 Months Ended

Apr. 30, 2019

Segment Reporting [Abstract]

BUSINESS SEGMENT INFORMATION

NOTE 13 — BUSINESS SEGMENT INFORMATION

The Company conducts business as two operating segments, Pharmaceuticals and Real Estate. The Company's reportable segments are distinguished by types of service, customers and methods used to provide their services. The operating results of these business segments are regularly reviewed by the Company's chief operating decision makers.

Beginning in the second quarter of fiscal 2018, the Pharmaceuticals segment is comprised of debt interests and a warrant to purchase equity interests in Rafael Pharmaceuticals and a majority equity interest in LipoMedix. Comparative results have been reclassified and restated as if the Pharmaceuticals segment existed for all periods presented. To date, the Pharmaceuticals segment has not generated any revenues.

The Real Estate segment consists of the Company's real estate holdings, including the building at 520 Broad Street in Newark, New Jersey that houses the Company and certain affiliates and its associated public garage, an office/data center building in Piscataway, New Jersey and a portion of an office building in Israel.

The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Pharmaceuticals segment based primarily on research and development efforts and results of clinical trials and the Real Estate segment based primarily on income (loss) from operations. All investments in Rafael Pharmaceuticals and assets and expenses associated with LipoMedix are tracked separately in the Pharmaceuticals segment. All corporate costs are allocated to the Real Estate segment.

Operating results for the business segments of the Company are as follows:

(unaudited, in thousands)	Pharmaceuticals			Real Estate			Total
Three months ended April 30, 2019
Revenues	$	—		$	1,377		$	1,377
Loss from operations		(311	)		(1,107	)		(1,418	)
Three months ended April 30, 2018
Revenues	$	—		$	1,093		$	1,093
Loss from operations		(258	)		(473	)		(731	)

(unaudited, in thousands)	Pharmaceuticals			Real Estate			Total
Nine months ended April 30, 2019
Revenues	$	—		$	3,529		$	3,529
Loss from operations		(1,014	)	$	(2,930	)		(3,944	)
Nine months ended April 30, 2018
Revenues	$	—		$	3,157		$	3,157
Loss from operations		(631	)		(1,969	)		(2,600	)

Geographic Information

Revenues from tenants located outside of the United States were generated entirely from related parties located in Israel. Revenues from these non-United States customers as a percentage of total revenues were as follows (revenues by country are determined based on the location of the related facility):

Three Months Ended April 30,	2019			2018
	(unaudited)
Revenue from tenants located in Israel		2	%		3	%

Nine Months Ended April 30,	2019			2018
	(unaudited)
Revenue from tenants located in Israel		2	%		5	%

Net long-lived assets and total assets held outside of the United States, which are located in Israel, were as follows:

(unaudited, in thousands)	United States		Israel		Total
April 30, 2019
Long-lived assets, net	$	47,502	$	1,679	$	49,181
Total assets		139,559		3,894		143,453
July 31, 2018
Long-lived assets, net	$	48,415	$	1,698	$	50,113
Total assets		113,279		3,641		116,920

XML

Commitments and Contingencies

9 Months Ended

Apr. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 14 — COMMITMENTS AND CONTINGENCIES

Legal Proceedings

On August 21, 2018, the Company entered into a settlement agreement with a building service provider in order to avoid the risks, delays and expenses inherent in and resulting from litigation. The $100,000 settlement was included in "Selling, general and administrative" expenses in the 2018 consolidated and combined statement of operations and in "Accrued Expenses" in the accompanying consolidated balance sheets. As the Company is fully indemnified by IDT for the settlement amount, a corresponding receivable was included in "Due to Related Parties" in the accompanying consolidated balance sheets. This amount has since been repaid in the first quarter of fiscal 2019.

Under a Founders Agreement among LipoMedix and other parties, two of LipoMedix' founders would become entitled to consulting payments in the approximate amounts of $385,000 and $358,000, respectively, upon the satisfaction of certain conditions thereto. LipoMedix believes that those conditions have not been satisfied and does not believe that they are likely to be satisfied until LipoMedix is successful in raising significant equity capital in the future.

On September 17, 2018, LipoMedix was notified of a claim initiated by one of its founders seeking payment of consulting fees in the amount of approximately $377,000 and seeking to place restrictions on LipoMedix' bank accounts and other assets to protect his claim. LipoMedix does not believe that the individual has the right to receive any payment at the current time. LipoMedix responded to the demand for the placement of restrictions on its assets. On November 26, 2018 the court denied the request by the founder to place restrictions on the assets. LipoMedix intends to vigorously defend this matter. LipoMedix and that founder are engaged in settlement discussions.  In May 2019, LipoMedix received a letter from the other founder requesting payment of his consulting fees.

The Company may from time to time be subject to legal proceedings that may arise in the ordinary course of business. Although there can be no assurance in this regard, the Company does not expect any of those legal proceedings to have a material adverse effect on the Company's results of operations, cash flows or financial condition.

XML

Stock Based Compensation

9 Months Ended

Apr. 30, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK BASED COMPENSATION

NOTE 15 — STOCK BASED COMPENSATION

Stock Options

Options to purchase 38,710 shares of Class B common stock were exercised during the nine months ended April 30, 2019. At April 30, 2019, there was no unrecognized compensation cost related to non-vested stock options.

Pursuant to the Company’s 2018 Equity Incentive Plan, each of the three non-employee directors of the Company were granted 4,203 restricted shares of our Class B common stock in January 2019 which fully vested on the date of the grant. The fair value of the awards on the date of the grant was approximately $107,000 which was included in selling, general and administrative expense.

Restricted Stock

The fair value of restricted shares of the Company’s Class B common stock is determined based on the closing price of the Company’s Class B common stock on the grant date. Share awards generally vest on a graded basis over three years of service.

A summary of the status of the Company’s grants of restricted shares of Class B common stock is presented below:

(unaudited)	Number of Non-vested Shares			Weighted-Average Grant-Date Fair Value
Outstanding at July 31, 2018		141,799		$	4.90
Granted		71,468			17.22
Vested		(60,010	)		4.90
Cancelled / Forfeited		—			—
NON-VESTED SHARES AT April 30, 2019		153,257		$	10.62

At April 30, 2019, there was $1.3 million of total unrecognized compensation cost related to non-vested stock-based compensation arrangements, which is expected to be recognized over 5 years. The total grant date fair value of shares vested in the nine months ended April 30, 2019 and 2018 was approximately $298,000 and $0, respectively.

XML

Future Minimum Rents

9 Months Ended

Apr. 30, 2019

Future Minimum Rents [Abstract]

FUTURE MINIMUM RENTS

NOTE 16 — FUTURE MINIMUM RENTS 

Certain of the Company’s properties are leased to tenants under net operating leases with initial term expiration dates ranging from 2021 to 2028. The future contractual minimum lease payments to be received (excluding operating expense reimbursements) by the Company as of April 30, 2019, under non-cancelable operating leases which expire on various dates through 2028, are as follows:

Year ending July 31,	Related Parties		Other		Total
(unaudited, in thousands)
2019	$	515	$	180	$	696
2020		1,992		1,054		3,046
2021		2,041		1,136		3,177
2022		2,078		993		3,071
2023		2,117		630		2,747
Thereafter		3,815		4,663		8,478
Total Minimum Future Rental Income	$	12,558	$	8,656	$	20,214

The Company has related party leases that expire in April 2025, for (i) an aggregate of 88,631 square feet, and which includes two parking spots per thousand square feet of space leased at 520 Broad Street, and (ii) 3,595 square feet in Israel. The annual rent is approximately $2.0 million in the aggregate. The related parties have the right to terminate the domestic leases upon four months’ notice, and upon early termination will pay a termination penalty equal to 25% of the portion of the rent due over the course of the remaining term. A related party has the right to terminate the Israeli lease upon four months’ notice. IDT has the right to lease an additional 50,000 square feet, in 25,000 foot increments, in the building located at 520 Broad Street on the same terms as their base lease, and other rights should 25,000 square feet or less remain available to lessees in the building. Upon expiration of the lease, related parties have the right to renew the leases for another five years.

XML

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Apr. 30, 2019

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The accompanying unaudited consolidated and combined financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included. Certain amounts in the prior period financial statements have been reclassified to conform with the current period presentation. These reclassifications had no effect on previously reported losses, total assets or stockholders equity.

The Company’s fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated (e.g., fiscal 2019 refers to the fiscal year ending July 31, 2019).

Operating results for the three and nine months ended April 30, 2019 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2019. The balance sheet at July 31, 2018 has been derived from the Company’s audited consolidated and combined financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended July 31, 2018, or the 2018 Form 10-K, as filed with the U.S. Securities and Exchange Commission (“SEC”).

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates.

Revenue Recognition

Revenue Recognition

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update, (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) or ASU 2014-09. The objective of the ASU is to establish a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers, which supersedes most of the existing revenue recognition guidance, including industry-specific guidance. The core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying the ASU, companies will perform a five-step analysis of transactions to determine when and how revenue is recognized. The five-step analysis consists of the following: (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations in the contract and (v) recognizing revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 applies to all contracts with customers except those that are within the scope of other topics in the FASB’s ASC. The Company adopted ASU 2014-09 effective August 1, 2018 using the modified retrospective approach. The Company reviewed all contracts that were not completed as of August 1, 2018 and the adoption did not have a material impact on the Company’s consolidated financial statements.

The Company disaggregates its revenue by source within its consolidated and combined statements of operations. As an owner and operator of real estate, the Company derives the majority of its revenue from leasing space to tenants at its properties. As a result, the majority of the Company’s revenue is accounted for pursuant to ASC 840 Leases or ASC 840 and is reflected within Rental Revenue in the consolidated and combined statements of operations. In addition, the Company earns revenue from recoveries from tenants, consisting of amounts due from tenants for common area maintenance, real estate taxes and other recoverable costs. Revenue from recoveries from tenants is recognized under the guidance within ASC 840 until the adoption of ASC 842, Leases in 2019 at which time it may fall within the guidance under Topic 606.

Contractual rental revenue is reported on a straight-line basis over the terms of the respective leases. Accrued rental income, included within Other Assets on the consolidated balance sheets, represents cumulative rental income earned in excess of rent payments received pursuant to the terms of the individual lease agreements. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent payments or parking customers to pay amounts due.

The Company also earns revenue from parking which is derived primarily from monthly and transient daily parking. In addition, the Company has certain lease arrangements for parking accounted for under the guidance in ASC 840. The monthly and transient daily parking revenue falls within the scope of ASC 606 and is accounted for at the point in time when control of the goods or services transfers to the customer and the Company’s performance obligation is satisfied, consistent with the Company’s previous accounting.

Recently Issued Accounting Pronouncements Not Yet Adopted

Recently Issued Accounting Pronouncements Not Yet Adopted

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of reviewing all contracts with suppliers, vendors, customers and other outside parties to identify whether such contracts contain an embedded lease as defined under the new guidance and whether there will be any impact of the pending adoption of the new standard on its consolidated financial statements. The Company intends to adopt the standard on August 1, 2019.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, that changes the impairment model for most financial assets and certain other instruments. For receivables, loans and other instruments, entities will be required to use a new forward-looking "expected loss" model that generally will result in the earlier recognition of allowance for losses. For available-for-sale debt securities with unrealized losses, entities will measure credit losses in a manner similar to current practice, except the losses will be recognized as allowances instead of reductions in the amortized cost of the securities. In addition, an entity will have to disclose significantly more information about allowances, credit quality indicators and past due securities. The new standard is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years and will be applied as a cumulative-effect adjustment to retained earnings. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and intends to adopt the standard on August 1, 2020.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash or ASU 2016-18. The new guidance is intended to reduce diversity in practice by adding or clarifying guidance on classification and presentation of changes in restricted cash on the statement of cash flows. ASU 2016-18 is effective for annual and interim periods beginning after December 15, 2017. The amendments in this Statement are required to be applied retrospectively to all periods presented. The Company adopted this guidance retrospectively on August 1, 2018 with no material impact on the Company's financial position, results of operations or cash flows. On a prospective basis, ASU 2016-18 will only impact the Company's financial position and cash flows to the extent it has restricted cash.

Recently Adopted Accounting Pronouncements

In January 2016, the FASB issued ASU 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which required us to prospectively record changes in the fair value of our equity investments, except for those accounted for under the equity method, in net income instead of in accumulated other comprehensive income.  The Company implemented ASU 2016-01 in the first quarter of fiscal 2019 effective August 1, 2018. A cumulative-effect adjustment was recorded as of August 1, 2018 to reclassify approximately $39,000 of unrealized loss on equity securities from accumulated other comprehensive income to retained earnings resulting in prior-periods no longer being comparable.

SEC Disclosure Update and Simplification

In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018. The first presentation of the changes in shareholders' equity in accordance with the new guidance is included in this Quarterly Report.

XML

Fair Value Measurments (Tables)

9 Months Ended

Apr. 30, 2019

Fair Value Disclosures [Abstract]

Schedule of balance of assets measured at fair value on a recurring basis

	April 30, 2019
	Level 1		Level 2		Level 3		Total
Available-for-sale securities:	(unaudited, in thousands)
Hedge Funds	$	—	$	—	$	4,632	$	4,632
Total	$	—	$	—	$	4,632	$	4,632

	July 31, 2018
	Level 1		Level 2		Level 3		Total
Available-for-sale securities:	(unaudited, in thousands)
Marketable Securities	$	10,755	$	13,946	$	—	$	24,701
Hedge Funds		—		—		4,218		4,218
Rafael Pharmaceuticals convertible promissory notes		—		—		7,900		7,900
Total	$	10,755	$	13,946	$	12,118	$	36,819

Schedule of assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3)

	Three Months Ended April 31,				Nine Months Ended April 31,
	2019		2018		2019			2018
	(unaudited, in thousands)
Balance, beginning of period	$	4,166	$	6,300	$	12,118		$	6,300
Conversion of Rafael Pharmaceuticals Series D Convertible Note		—		—		(7,900	)		—
Total gains included in earnings		466		—		414			—
Balance, end of period	$	4,632	$	6,300	$	4,632		$	6,300

XML

Trade Accounts Receivable (Tables)

9 Months Ended

Apr. 30, 2019

Receivables [Abstract]

Schedule of trade accounts receivable

	April 30, 2019			July 31, 2018
	(unaudited, in thousands)
Trade Accounts Receivable – Third Party	$	747		$	358
Trade Accounts Receivable – Related Party		11			11
Less Allowance for Doubtful Accounts		(86	)		(82	)
Trade Accounts Receivable, net	$	672		$	287

XML

Property and Equipment (Tables)

9 Months Ended

Apr. 30, 2019

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

	April 30, 2019			July 31, 2018
	(unaudited, in thousands)
Building and Improvements	$	53,118		$	52,818
Land		10,412			10,412
Furniture and Fixtures		1,145			1,145
Other		255			255
Construction in Progress		1,095			1,024
Less Accumulated Depreciation		(16,844	)		(15,541	)
Total	$	49,181		$	50,113

XML

Loss Per Share (Tables)

9 Months Ended

Apr. 30, 2019

Loss Per Share [Abstract]

Schedule of dilutive loss per share

	April 30, 2019		July 31, 2018
	(unaudited)
Stock Options		573,127		626,580
Convertible Note		1,770,956		—
Total		2,344,083		626,580

XML

Related Party Transactions (Tables)

9 Months Ended

Apr. 30, 2019

Related Party Transactions [Abstract]

Schedule of change in the Company's liability to related parties

	Due to IDT			Due from Rafael Pharmaceuticals
	(unaudited, in thousands)
Balance at January 31, 2019	$	40		$	(40	)
Payments by IDT on behalf of the Company		52			—
Rental revenue billed to Related Parties		(473	)		—
Cash repayments, net of advances		425			—
Billings for services performed for Rafael Pharmaceuticals		—			(120	)
Balance at April 30, 2019	$	44		$	(160	)

Schedule of consolidated and combined statements of operations

	April 30, 2019
Convertible Note:	(unaudited, in thousands)
Principal value of 6% convertible note at April 30, 2019, due November 15, 2021	$	15,000
Debt discount		(60	)
Total long-term carrying value of convertible note	$	14,940

XML

Business Segment Information (Tables)

9 Months Ended

Apr. 30, 2019

Segment Reporting [Abstract]

Schedule of operating results for the business segments

(unaudited, in thousands)	Pharmaceuticals			Real Estate			Total
Three months ended April 30, 2019
Revenues	$	—		$	1,377		$	1,377
Loss from operations		(311	)		(1,107	)		(1,418	)
Three months ended April 30, 2018
Revenues	$	—		$	1,093		$	1,093
Loss from operations		(258	)		(473	)		(731	)

(unaudited, in thousands)	Pharmaceuticals			Real Estate			Total
Nine months ended April 30, 2019
Revenues	$	—		$	3,529		$	3,529
Loss from operations		(1,014	)	$	(2,930	)		(3,944	)
Nine months ended April 30, 2018
Revenues	$	—		$	3,157		$	3,157
Loss from operations		(631	)		(1,969	)		(2,600	)

Schedule of revenue from tenants by geographic areas

Three Months Ended April 30,	2019			2018
	(unaudited)
Revenue from tenants located in Israel		2	%		3	%

Nine Months Ended April 30,	2019			2018
	(unaudited)
Revenue from tenants located in Israel		2	%		5	%

Schedule of net long-lived assets and total assets by geographic areas

United States			Israel			Total
April 30, 2019
Long-lived assets, net	$	47,502		$	1,679		$	49,181
Total assets		139,559			3,894			143,453
July 31, 2018
Long-lived assets, net	$	48,415		$	1,698		$	50,113
Total assets		113,279			3,641			116,920

XML

Stock Based Compensation (Tables)

9 Months Ended

Apr. 30, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of grants of restricted shares of Class B common stock

(unaudited)	Number of Non-vested Shares			Weighted-Average Grant-Date Fair Value
Outstanding at July 31, 2018		141,799		$	4.90
Granted		71,468			17.22
Vested		(60,010	)		4.90
Cancelled / Forfeited		—			—
NON-VESTED SHARES AT April 30, 2019		153,257		$	10.62

XML

Future Minimum Rents (Tables)

9 Months Ended

Apr. 30, 2019

Future Minimum Rents [Abstract]

Schedule of non-cancelable operating leases

Year ending July 31,	Related Parties		Other		Total
(unaudited, in thousands)
2019	$	515	$	180	$	696
2020		1,992		1,054		3,046
2021		2,041		1,136		3,177
2022		2,078		993		3,071
2023		2,117		630		2,747
Thereafter		3,815		4,663		8,478
Total Minimum Future Rental Income	$	12,558	$	8,656	$	20,214

XML

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Jul. 31, 2018
Description of Business and Basis of Presentation (Textual)
Adoption effect of ASU 2016-01	$ 39
Common Class B [Member]
Description of Business and Basis of Presentation (Textual)
Common stock, shares issued	13,139,333		11,762,346
Common stock, shares outstanding	13,139,333		11,762,346
Common Class A [Member]
Description of Business and Basis of Presentation (Textual)
Common stock, shares issued	787,163		787,163
Common stock, shares outstanding	787,163		787,163

XML

Investment in LipoMedix (Details) - LipoMedix [Member] - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Jul. 31, 2018	Jan. 31, 2018	Apr. 30, 2019
Issued and outstanding ordinary shares, percentage		50.60%
Initial investment	$ 875
Description of acquisition entity	(i) upon an issuance of an aggregate $2.0 million of additional equity securities (excluding the conversion of the 2018 Bridge Note) (the "Financing"), the 2018 Bridge Note amount shall be converted into shares of LipoMedix of the same class and series with the same rights, preferences and privileges as shall be issued in the Financing at a conversion price per share equal to 75% or the lowest price per share paid by the investor(s) in the Financing; (ii) upon a Distribution Event (as defined in the Founder's Agreement among LipoMedix and certain of its founders), the 2018 Bridge Note shall be converted into shares of the most senior class of shares of LipoMedix then issued, at a conversion price per share that is equal to 75% of the per share distribution received by LipoMedix equity holders in connection with the Distribution Event, or the Company shall be entitled to receive a redemption payment equal to the 2018 Bridge Note ($875,000); (iii) if neither a Financing nor Distribution Event occurs prior to January 6, 2020 (18 months following the effective date of the 2018 Bridge Note), the 2018 Bridge Note will be converted into the most senior class of shares LipoMedix has then issued at a conversion price per share equal to $0.53 (calculated on the basis of LipoMedix's pre-money valuation of $5.0 million, divided by its fully diluted share capital as of July 6, 2018).		(i) upon an issuance of an aggregate $2.0 million of additional equity securities (excluding the conversion of the Bridge Notes); or (ii) upon a liquidation or dissolution of LipoMedix or a sale of LipoMedix or its assets.  If converted, the 2019 Bridge Note will be converted into shares of the most senior class of equity of LipoMedix then issued.  If converted upon an equity financing, the 2019 Bridge Note will be converted at a conversion price per share that is equal to 75% of the price paid in the equity offering. If converted upon a liquidation or sale event, the 2019 Bridge Note will be converted at a conversion price per share that is equal to 75% of the per share distribution received by LipoMedix equity holders in connection with the event, or, if greater the Company will receive a payment equal to the 2019 Bridge Note ($250,000).  If none of such events occurs prior to September 28, 2019, the 2019 Bridge Note will be converted into the most senior class of shares LipoMedix has then issued at a conversion price per share equal to $0.53 (calculated on the basis of LipoMedix's pre-money valuation of $5.0 million).
No-interest bridge financing			$ 250

XML

Marketable Securities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Marketable Securities (Textual)
Proceeds from maturities and sales of available-for-sale securities	$ 0	$ 436	$ 25,000	$ 436
Net realized gain	$ 0	$ 24	$ 330	$ 24

XML

Fair Value Measurments (Details) - USD ($) $ in Thousands	Apr. 30, 2019	Jul. 31, 2018
Available-for-sale securities:
Marketable Securities		$ 24,701
Hedge Funds	4,632	4,218
Rafael Pharmaceuticals convertible promissory notes		7,900
Total	4,632	36,819
Level 1 [Member]
Available-for-sale securities:
Marketable Securities		10,755
Hedge Funds
Rafael Pharmaceuticals convertible promissory notes
Total		10,755
Level 2 [Member]
Available-for-sale securities:
Marketable Securities		13,946
Hedge Funds
Rafael Pharmaceuticals convertible promissory notes
Total		13,946
Level 3 [Member]
Available-for-sale securities:
Marketable Securities
Hedge Funds	4,632	4,218
Rafael Pharmaceuticals convertible promissory notes		7,900
Total	$ 4,632	$ 12,118

XML

Fair Value Measurments (Details 1) - Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Defined Benefit Plan Disclosure [Line Items]
Balance, beginning of period	$ 12,118	$ 6,300	$ 4,166	$ 6,300
Conversion of Rafael Pharmaceuticals Series D Convertible Note	(7,900)
Total gains included in earnings	414		466
Balance, end of period	$ 4,632	$ 6,300	$ 4,632	$ 6,300

XML

Fair Value Measurments (Details Textual) $ in Thousands	Apr. 30, 2019 USD ($)
Fair Value Measurements (Textual)
Spin-Off, IDT contribution investment amount	$ 2,000

XML

Trade Accounts Receivable (Details) - USD ($) $ in Thousands	Apr. 30, 2019	Jul. 31, 2018
Receivables [Abstract]
Trade Accounts Receivable – Third Party	$ 747	$ 358
Trade Accounts Receivable – Related Party	11	11
Less Allowance for Doubtful Accounts	(86)	(82)
Trade Accounts Receivable, net	$ 672	$ 287

XML

Trade Accounts Receivable (Details Textual) - USD ($) $ in Thousands	Apr. 30, 2019	Jul. 31, 2018
Prepaid expenses and other current assets	$ 840	$ 421
Other assets	1,223	1,126
Noncurrent accrued rental income [Member]
Other assets	1,200	1,000
Accrued rental income [Member]
Prepaid expenses and other current assets	$ 334	$ 88

XML

Property and Equipment (Details) - USD ($) $ in Thousands	Apr. 30, 2019	Jul. 31, 2018
Property, Plant and Equipment [Abstract]
Building and Improvements	$ 53,118	$ 52,818
Land	10,412	10,412
Furniture and Fixtures	1,145	1,145
Other	255	255
Construction in Progress	1,095	1,024
Less Accumulated Depreciation	(16,844)	(15,541)
Total	$ 49,181	$ 50,113

XML

Property and Equipment (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Property and Equipment (Textual)
Depreciation and amortization expense pertaining to property and equipment	$ 436	$ 422	$ 1,296	$ 1,276

XML

Loss Per Share (Details) - shares	9 Months Ended	12 Months Ended
	Apr. 30, 2019	Jul. 31, 2018
Loss Per Share [Abstract]
Stock Options	573,127	626,580
Convertible Note	1,770,956
Total	2,344,083	626,580

XML

Establishment of Valuation Allowance for Deferred Tax Asset (Details) $ in Thousands	9 Months Ended
	Apr. 30, 2019 USD ($)
Establishment of Valuation Allowance for Deferred Tax Asset (Textual)
Valuation allowance	$ 8,400

XML

Investment in Rafael Pharmaceuticals (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Sep. 19, 2017	Apr. 30, 2019
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Convertible promissory note, maturity date		Nov. 15, 2021
IDT-Rafael Holdings, LLC. [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership percentage in non-operating subsidiary		50.00%
Percentage of capital stock	10.00%
Percentage of bonus shares received		10.00%
Fully diluted		51.00%
Bonus shares		39.50%
IDT-Rafael Holdings, LLC. [Member] | Series D Convertible Preferred Stock [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership percentage in non-operating subsidiary		90.00%
Exercise of warrants purchases, description		The Series D Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the board of Rafael Pharmaceuticals, prior to any dividends to any other class of capital stock of Rafael Pharmaceuticals. In the event of any liquidation, dissolution or winding up of the Company, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution, winding up shall be distribute first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class.
Warrants expiry date		Dec. 31, 2020
Exercise price of warrants or rights, description		IDT-Rafael Holdings holds 36.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase ownership to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the “Warrant”). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share.
Purchase of exercise the warrant, shares		16,700,000
IDT-Rafael Holdings, LLC. [Member] | Howard S. Jonas [Member] | Series C Convertible Notes [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Principal amount		$ 525
IDT-Rafael Holdings, LLC. [Member] | Howard Jonas and Deborah Jonas [Member] | Series C Convertible Notes [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Principal amount		$ 525
CS Pharma Holdings, LLC [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership percentage in non-operating subsidiary		50.00%
Ownership percentage in subsidiary and holds percentage of interest		90.00%
Indirect interest in assets held, percentage		45.00%

XML

Related Party Transactions (Details) $ in Thousands	3 Months Ended
	Apr. 30, 2019 USD ($)
Ending Balance	$ 160
Due to IDT [Member]
Beginning Balance	40
Payments by IDT on behalf of the Company	52
Rental revenue billed to Related Parties	(473)
Cash repayments, net of advances	425
Ending Balance	44
Due from Rafael Pharmaceuticals [Member]
Beginning Balance	(40)
Billings for services performed for Rafael Pharmaceuticals	(120)
Ending Balance	$ (160)

XML

Related Party Transactions (Details 1) - USD ($) $ in Thousands	Apr. 30, 2019	Jul. 31, 2018
Related Party Transactions
Principal value of 6% convertible note at April 30, 2019, due November 15, 2021	$ 15,000
Debt discount	(60)
Total long-term carrying value of convertible note	$ 14,940

XML

Related Party Transactions (Details Textual) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Apr. 30, 2019	Apr. 30, 2019	Jul. 31, 2018
Related Party Transactions (Textual)
Percentage of convertible note		6.00%
Convertible note due date		Nov. 15, 2021
Due to related parties	$ 44	$ 44
Due from Rafael Pharmaceuticals	160	160
At issuance [Member]
Related Party Transactions (Textual)
Debt discount to the beneficial conversion feature		70
Amortized discount		10
Interest expense on note	$ 228	$ 418
Howard S. Jonas [Member]
Related Party Transactions (Textual)
Deposit amount			$ 864
Convertible note, description		On November 15, 2018, Howard Jonas entered into an agreement to purchase a convertible note from the “Company” for $15.0 million. The term of the note is three years and interest will accrue on the principal amount at a rate of 6% per annum, compounded quarterly. At the option of the Company, interest on the note can be capitalized and added to principal or payable in cash. The note is convertible at the option of the holder into shares of Class B common stock at a conversion price of $8.47 per share, the closing price of the Company’s Class B common stock on the trading day before the date of the investment agreement. The initial principal amount is convertible into 1,770,956 shares of Class B common stock, and if all interest for the three-year term of the note is capitalized, the note will be convertible into 2,117,388 shares of Class B common stock. If the closing price of the Company’s Class B common stock on the NYSE American is 200% of the conversion price for at least thirty (30) consecutive days, the Company may cause conversion of the note.

XML

Income Taxes (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Jul. 31, 2018	Apr. 30, 2019
Income Taxes (Textual)
Federal statutory corporate tax, description		The Tax Act provides for comprehensive tax legislation that, among other things, reduces the U.S. federal statutory corporate tax rate from 35.0% to 21.0% effective January 1, 2018, broadens the U.S. federal income tax base, requires companies to pay a one-time repatriation tax on earnings of certain foreign subsidiaries that were previously tax deferred ("transition tax"), and creates new taxes on certain foreign sourced earnings.
Federal and state net operating loss	$ 20,000
Federal and state net operating loss, expiration date	Jul. 31, 2026
Additional losses of domestic operations		$ 1,500
Net deferred tax assets operating loss carryforwards		$ 22,100

XML

Business Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Segment Reporting Information [Line Items]
Revenues	$ 1,377	$ 1,093	$ 3,529	$ 3,157
Loss from operations	(1,418)	(731)	(3,944)	(2,600)
Real Estate [Member]
Segment Reporting Information [Line Items]
Revenues	1,377	1,093	3,529	3,157
Loss from operations	1,107	(473)	2,930	(1,969)
Pharmaceuticals [Member]
Segment Reporting Information [Line Items]
Revenues
Loss from operations	$ 311	$ (258)	$ 1,014	$ (631)

XML

Business Segment Information (Details 1)	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Total revenues [Member]
Segment Reporting Information [Line Items]
Revenue from tenants located in Israel	2.00%	3.00%	2.00%	5.00%

XML

Business Segment Information (Details 2) - USD ($) $ in Thousands	Apr. 30, 2019	Jul. 31, 2018
Segment Reporting Information [Line Items]
Long-lived Assets, net	$ 49,181	$ 50,113
Total Assets	143,453	116,920
United States [Member]
Segment Reporting Information [Line Items]
Long-lived Assets, net	47,502	48,415
Total Assets	139,559	113,279
Israel [Member]
Segment Reporting Information [Line Items]
Long-lived Assets, net	1,679	1,698
Total Assets	$ 3,894	$ 3,641

XML

Business Segment Information (Details Textual)	9 Months Ended
	Apr. 30, 2019 Segments
Business Segment Information (Textual)
Number of operating segments	2

XML

Commitments and Contingencies (Details) - USD ($) $ in Thousands	Sep. 17, 2018	Aug. 21, 2018
Commitments and Contingencies (Textual)
Settlement expenses		$ 100
LipoMedix Pharmaceuticals Ltd [Member]
Commitments and Contingencies (Textual)
Consulting payments amounts		385
LipoMedix Pharmaceuticals Ltd [Member]
Commitments and Contingencies (Textual)
Payment of consulting fees	$ 377
Other parties [Member]
Commitments and Contingencies (Textual)
Consulting payments amounts		$ 358

XML

Stock Based Compensation (Details)	9 Months Ended
	Apr. 30, 2019 $ / shares shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Non-vested Shares, Beginning Balance | shares	141,799
Number of Non-vested Shares, Granted | shares	71,468
Number of Non-vested Shares, Vested | shares	(60,010)
Number of Non-vested Shares, Cancelled / Forfeited | shares
Number of Non-vested Shares, Ending Balance | shares	153,257
Weighted- Average Grant- Date Fair Value, Beginning balance | $ / shares	$ 4.90
Weighted- Average Grant- Date Fair Value, Granted | $ / shares	17.22
Weighted- Average Grant- Date Fair Value, Vested | $ / shares	4.90
Weighted- Average Grant- Date Fair Value, Cancelled / Forfeited | $ / shares
Weighted- Average Grant- Date Fair Value, Ending balance | $ / shares	$ 10.62

XML

Stock Based Compensation (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018
Stock-Based Compensation (Textual)
Total unrecognized non-vested stock-based compensation	$ 1,300
Total grant date fair value of shares vested	$ 298	$ 0
Non-vested stock options, weighted-average period	5 years
Common Class B [Member]
Stock-Based Compensation (Textual)
Number of options exercised	38,710
2018 Equity Incentive Plan [Member] | Three non-employee directors [Member]
Stock-Based Compensation (Textual)
Granted restricted shares	4,203
Fair value of awards on date of grant included in selling, general and administrative expense	$ 107

XML

Future Minimum Rents (Details) $ in Thousands	Apr. 30, 2019 USD ($)
2019	$ 696
2020	3,046
2021	3,177
2022	3,071
2023	2,747
Thereafter	8,478
Total Minimum Future Rental Income	20,214
Related Parties [Member]
2019	515
2020	1,992
2021	2,041
2022	2,078
2023	2,117
Thereafter	3,815
Total Minimum Future Rental Income	12,558
Other [Member]
2019	180
2020	1,054
2021	1,136
2022	993
2023	630
Thereafter	4,663
Total Minimum Future Rental Income	$ 8,656

XML

Future Minimum Rents (Details Textual) $ in Thousands	9 Months Ended
	Apr. 30, 2019 USD ($)
Future Minimum Rents (Textual)
Net operating leases with initial term expiration dates	Dates ranging from 2021 to 2028.
Related party leases expire, description	The Company has related party leases that expire in April 2025, for (i) an aggregate of 88,631 square feet, and which includes two parking spots per thousand square feet of space leased at 520 Broad Street, and (ii) 3,595 square feet in Israel.
Annual rent	$ 2,000
Related parties terminate leases, description	A related party has the right to terminate the Israeli lease upon four months’ notice. IDT has the right to lease an additional 50,000 square feet, in 25,000 foot increments, in the building located at 520 Broad Street on the same terms as their base lease, and other rights should 25,000 square feet or less remain available to lessees in the building. Upon expiration of the lease, related parties have the right to renew the leases for another five years.